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 Abstract 
 Many cell types were known to have migratory properties towards tumors and different 
research groups have shown reliable results regarding cells as delivery vehicles of therapeutics 
for targeted cancer treatment. Present report discusses proof of concept for 1. Cell mediated 
delivery of Magnetic nanoparticles (MNPs) and targeted Magnetic hyperthermia (MHT) as a 
cancer treatment by using in vivo mouse cancer models, 2. Cells surface engineering with 
chimeric proteins for targeted cancer treatment by using in vitro models. 1. Tumor homing cells 
can carry MNPs specifically to the tumor site and tumor burden will decrease after 
alternating magnetic field (AMF) exposure. To test this hypothesis, first we loaded Fe/Fe3O4 
bi-magnetic NPs into neural progenitor cells (NPCs), which were previously shown to migrate 
towards melanoma tumors. We observed that NPCs loaded with MNPs travel to subcutaneous 
melanoma tumors. After alternating magnetic field (AMF) exposure, the targeted delivery of 
MNPs by the NPCs resulted in a mild decrease in tumor size (Chapter-2). 
Monocytes/macrophages (Mo/Ma) are known to infiltrate tumor sites, and also have phagocytic 
activity which can increase their uptake of MNPs. To test Mo/Ma-mediated MHT we 
transplanted Mo/Ma loaded with MNPs into a mouse model of pancreatic peritoneal 
carcinomatosis. We observed that MNP-loaded Mo/Ma infiltrated pancreatic tumors and, after 
AMF treatment, significantly prolonged the lives of mice bearing disseminated intraperitoneal 
pancreatic tumors (Chapter-3). 2. Targeted cancer treatment could be achieved by 
engineering tumor homing cell surfaces with tumor proteases cleavable, cancer cell specific 
recombinant therapeutic proteins. To test this, Urokinase and Calpain (tumor specific 
proteases) cleavable; prostate cancer cell (CaP) specific (CaP1 targeting peptide); apoptosis 
inducible (Caspase3 V266ED3)-  rCasp3V266ED3 chimeric protein was designed in silico.  
Hypothesized membrane anchored chimeric protein (rCasp3V266ED3, rMcherry red) plasmids 
were constructed. Membrane anchoring and activity of designed proteins were analyzed in 
RAW264.7 Mo/Ma and HEK293 cells in vitro. Further, Urokinase (uPA) mediated cleavage and 
release of rCasp3V266ED3 from engineered cells was tested (Chapter-4).  Animal models for 
cancer therapy are invaluable for preclinical testing of potential cancer treatments. Final chapter 
of present report shows evidence for immune-deficient line of pigs as a model for human 
cancers (Chapter-5) 
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 Abstract 
Many cell types were known to have migratory properties towards tumors and different 
research groups have shown reliable results regarding cells as delivery vehicles of therapeutics 
for targeted cancer treatment. Present report discusses proof of concept for 1. Cell mediated 
delivery of Magnetic nanoparticles (MNPs) and targeted Magnetic hyperthermia (MHT) as a 
cancer treatment by using in vivo mouse cancer models, 2. Cells surface engineering with 
chimeric proteins for targeted cancer treatment by using in vitro models. 1. Tumor homing cells 
can carry MNPs specifically to the tumor site and tumor burden will decrease after 
alternating magnetic field (AMF) exposure. To test this hypothesis, first we loaded Fe/Fe3O4 
bi-magnetic NPs into neural progenitor cells (NPCs), which were previously shown to migrate 
towards melanoma tumors. We observed that NPCs loaded with MNPs travel to subcutaneous 
melanoma tumors. After alternating magnetic field (AMF) exposure, the targeted delivery of 
MNPs by the NPCs resulted in a mild decrease in tumor size (Chapter-2). 
Monocytes/macrophages (Mo/Ma) are known to infiltrate tumor sites, and also have phagocytic 
activity which can increase their uptake of MNPs. To test Mo/Ma-mediated MHT we 
transplanted Mo/Ma loaded with MNPs into a mouse model of pancreatic peritoneal 
carcinomatosis. We observed that MNP-loaded Mo/Ma infiltrated pancreatic tumors and, after 
AMF treatment, significantly prolonged the lives of mice bearing disseminated intraperitoneal 
pancreatic tumors (Chapter-3). 2. Targeted cancer treatment could be achieved by 
engineering tumor homing cell surfaces with tumor proteases cleavable, cancer cell specific 
recombinant therapeutic proteins. To test this, Urokinase and Calpain (tumor specific 
proteases) cleavable; prostate cancer cell (CaP) specific (CaP1 targeting peptide); apoptosis 
inducible (Caspase3 V266ED3)-  rCasp3V266ED3 chimeric protein was designed in silico.  
Hypothesized membrane anchored chimeric protein (rCasp3V266ED3, rMcherry red) plasmids 
were constructed. Membrane anchoring and activity of designed proteins were analyzed in 
RAW264.7 Mo/Ma and HEK293 cells in vitro. Further, Urokinase (uPA) mediated cleavage and 
release of rCasp3V266ED3 from engineered cells was tested (Chapter-4).  Animal models for 
cancer therapy are invaluable for preclinical testing of potential cancer treatments. Final chapter 
of present report shows evidence for immune-deficient line of pigs as a model for human 
cancers (Chapter-5).
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Chapter 1 - Introduction & Literature review 
 Introduction 
Cancer is one of the leading causes of deaths in worldwide [1]. Compared with other 
diseases and pathological conditions biology of cancer disease is complex [2, 3]. Although many 
research groups are working to understand the biology of cancer, the information we know about 
the disease is not complete [2]. In starting, cancer cells were known as normal cells that lost their 
control over cell dividing ability and form disorganized tissues called tumors [4]. These cells 
acquire ability to migrate to other parts of the body and can form metastatic tumors eventually 
lead to problems in the physiology of whole animal [4]. But with extensive research with human 
and mouse cancer models, the number of biological characteristics identified with cancer cells 
and their malignant tumors were increased and still increasing [4]. As Weinberg et al., models 
every few years about cancer disease with his “Hallmarks of cancer” title, the number of 
characteristics that were identified with cancer cells are as follows- sustained proliferative 
signaling, evading growth suppressors, resisted to cell death , enabling replicative immortality, 
inducing angiogenesis, activating invasion and metastasis [2, 4]. Cancer cells acquire these 
properties by genomic instability causing mutations in important genes [2, 4]. Apart from these 
genetic mutations cancer cells cause recruitment of normal cells that contribute to malignant 
tumor with favorable microenvironment formation [2, 4, 5]. With present understanding, cancer 
tissue was defined as more of disorganized tissue system that have cancer cells as parenchymal 
cells with different kinds of supporting cells, immune cells and stem/progenitor cells [5]. Again 
above mentioned properties acquisition and expression is different between different types of 
cancers [2].  
Urgency of treating cancer patients led to the discovery of treatments such as surgery, 
chemotherapy and radiation therapy in 19
th
 and 20
th
 century and they are still the predominant 
procedures used in clinics [6, 7] . These treatments were rationalized based on the primary 
observation of unstoppable dividing ability of cancer cells and abnormal tumor growth [7]. 
Clinicians were using these treatments with or without adjuvant therapies based on type of 
cancer and its stage at the time of diagnosis [7]. Although these treatments/treatment 
combinations giving remission from the disease for some period of time, relapse of the disease 
and the side effects caused from these treatments making them as not an ideal option for cancer 
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treatment [7]. Lack of treatments that can target specifically to cancer cells or malignant tumors, 
made these treatments still as dominant ones in cancer therapy [7] . 
Comparatively increased understanding of cancer cells and malignant tumor 
characteristics led to discovery of chemicals and proteins that have cancer cell specificity [7].  
For example identification of Philadelphia chromosome mutation and Gleevec (tyrosine kinase 
inhibitor), Her2 receptor over expressing tumors and Trastuzumab (antibody against Her2 
receptor -Herceptin) [7]. Identification of mutated genes and their proteins dis-functionality in 
different types of cancers helped in designing therapeutics that can interact with these abnormal 
proteins to achieve cancer cell specific treatments [2]. These targeted treatments worked only for 
few types of malignant tumors, because of the differences in number of mutated genes and 
variability in the genes that were mutated in different types of cancer cells [2, 3]. Treatments 
with these higher rationale chemicals or proteins helped at some level in cancer therapy, but still 
they didn’t solve all the problems and lots of these treatments have significant side effects. 
Problems associated with small molecular drugs and protein therapeutics are like 
pharmacodynamics (PD) & pharmacokinetics (PK) of injected therapeutics and  level of 
targeting towards malignant tumors & cancer cells [8]. Although, Nanoparticle based 
therapeutics were proposed to solve above mentioned problems still the amount of targeting that 
can be achieved with nanoparticles may not be enough and  PD,PK associated problems will still 
be there [8]. 
Tumor stroma contains supporting cells, stromal cells, immune cells that helps cancer 
cells in complete formation of cancer tissue [2, 5]. During malignant tumor formation these 
supporting cells migrate to that place and help cancer cells by directly assisting their growth or 
constructing environment that helps in tumor tissue formation [2, 5]. Cancer cells with stromal 
cells secrete cytokines that helps in migration of different cells into tumor environment [5]. By 
using these cells as delivery vehicles problems associated with available therapies can be solved. 
Migrating ability of cells towards cancer tissue increases the targeting efficiency of therapeutics 
towards tumors, which is the main problem in available cancer therapeutics. Cell mediated 
therapeutics my not have PD, PK related issues because of their directed migration towards 
tumor tissues[8]. Several research groups have been used this hypothesis and tested different cell 
mediated delivery of therapeutics in pre-clinical mouse cancer models [9, 10]. Based on this 
background information hypothesis were proposed and tested in this present dissertation. In 
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chapter-2& 3 tumor homing cells mediated targeted Magnetic hyperthermia system was tested 
and in Chapter-4 tumor homing cells mediated chimeric protein therapeutic system was tested. 
 Literature Review 
 Cell mediated delivery of therapeutics 
Multiple cell types were known to contribute in important ways to the formation of 
tumors and its microenvironment [2, 5]. Cancer associated fibroblasts, Angiogenic vascular cells 
and infiltrating immune cells are the three major cell types that were identified in tumor stroma 
[2]. During tumorigenesis cytokines released from cancer cells and its resident stromal cell types 
involve in recruitment of these tumor stromal cells [2, 5]. These recruited tumor stromal cells can 
variably contribute to, or in some cases oppose, acquisition of identified hallmarks of cancer [5].  
Neonatal or adult tissue derived Mesenchymal stem cells (MSCs) [11], Neural stem cells (NSCs) 
[12], Macrophages [13] are the cell types that were used extensively in pre-clinical testing for 
cell mediated therapeutic delivery hypothesis till date. Apart from these cells there were few 
reports on MDSCs (myeloid derived suppressor cells) [14] and endothelial cells [15] as delivery 
vehicles. Signaling molecules that were known to cause recruitment of tumor stromal cells 
involve in tumor tropic ability of above mentioned cell types [5, 11, 12]. Although a definitive 
mechanism for these cells homing (recruitment, rolling, arrest, transmigration) into tumor 
microenvironment yet to be fully elucidated, studies have shown that cytokines like vascular 
endothelial growth factor (VEGF), CC chemokine ligand, CCL5/RANTES, angiopoietin 2 
released from tumors into circulation guide the migration of receptor positive cells [5, 11, 12].  
Therapeutic systems that were tested till date by using tumor homing cells as delivery vehicles 
are as follows; Antitumor cytokines, Gene directed prodrug therapy systems, Antibodies, 
Oncolytic viruses, Nanoparticles, Drugs, Radiation therapy and Photodynamic therapy 
 Antitumor cytokines 
Antitumor cytokines are signaling molecules comprised of proteins, peptides, 
glycoproteins that are produced by immune cells that can cause antitumor (immune) response 
[16]. Cytokines that were known to have antitumor properties that were tested in pre-clinical and 
clinical trials are- Interleukins ( IL-2,3,4,6,7,10,12,13,15,18), Colony stimulating factors (M-
CSF, GM-CSF) , Interferons (α, γ) , Tumor necrosis factors (TNF-α), TGF-β, TRAIL, 
4 
 
lymphotactin, FLT3 ligand[16]. Systemic delivery of these antitumor cytokines was thought to 
be viable cancer treatment, but yielded different side effects [16]. Tumor homing cells could be 
engineered to secrete these cytokines and targeted delivery could be achieved that can decrease 
systemic delivery mediated side effects and can potentiate those cytokines antitumor effect. 
Many research groups tested this hypothesis by engineering tumor homing cells with secreted 
antitumor cytokines like IFN-β [17-20], IFN-γ [9, 19-21] , IL-12 [20, 22-24] , TRAIL [20, 25-
33], IL-18 [20, 34] , CX3CL-1 [35, 36] on different mouse/rat cancer models and showed 
convincing results. Targeted combination therapies like engineering cells to express two or more 
cytokines / cytokines and other therapeutics were also reported in literature [18, 28]. Most of 
studies that were mentioned above used either Mesenchymal stem cells (MSCs) or neural stem 
cells (NSCs) as delivery vehicles. 
 Gene directed enzyme/prodrug therapy (GDEPT) 
Gene-directed enzyme/prodrug therapy (GDEPT) has been used with varying levels of 
success to achieve targeted cancer therapy [37, 38]. This strategy uses a vector targeted gene for 
an enzyme that will convert a relatively inactive prodrug to its active drug counterpart [37, 38]. 
Two steps are needed for this to happen. First, the gene that can make the enzyme must be 
targeted to or produced by the tumors and the prodrug then needs to be delivered to the tumor for 
activation [39]. Enzyme/prodrug systems that were tested in clinical trials are- Herpes simplex 
virus thymidine kinase / Ganciclovir (HSVtk / GV), Cytosine deaminase / 5-Fluoro cytosine 
(CD/5FC), Nitroreductase / CB1954, Cytochrome P450 / Cyclophosphamide, Carboxy peptidase 
G2 / CMDA, Horseradish peroxidase / Indole 3-acetic acid, Carboxyl esterase / ironotecan 
(CE/CPT-11) [39]. Although, improvements in the gene targeting methods helped in this system 
as a targeted cancer treatment, still there are problems that need to be clarified [39]. Tumor 
homing cells could be engineered to secrete these enzymes and can convert the prodrug into 
drugs specifically in tumor environment. Research groups have tested HSVtk / GV, CE/CPT-11, 
CD/5FC systems by using cells like MSCs, NSCs and macrophages on mouse cancer models 
[40-45]. Targeted combination therapies like engineering cells to express antitumor cytokine / 
prodrug converting enzyme were also reported in literature [46, 47]. 
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 Therapeutic Antibodies 
Monoclonal antibodies (mAbs) based cancer therapy achieved considerable success in 
recent years [48]. Pharmacokinetics (PK), size and immunogenicity of designed antibodies are 
associated problems in antibody therapy of cancer [48]. By engineering tumor homing cells to 
secrete these antibodies, above mentioned problems could be escaped. As a proof of this concept, 
engineered neural stem cells expressing Trastuzumab showed significant outcome in HER2 
expressing breast cancer models than systemic administration of Trastuzumab [49].  
 Oncolytic virotherapy 
Oncolytic virotherapy is a novel approach in which viruses are genetically modified to 
selectively replicate in tumor cells [50]. These viruses can distinguish tumors from normal 
tissues and induce tumor cell specific oncolysis [50]. A number of oncolytic viruses (OVs) 
showed antitumor activity in pre-clinical and clinical trials in past two decades [51]. But, host 
antiviral immune response and inefficient distribution OVs were preventing the advancement in 
oncolytic virotherapy [52]. Cell mediated delivery of these OVs can solve the immune response 
and distribution related problems. MSCs [52], NSCs [52], MDSCs [14], Macrophages [13] were 
successfully used as delivery vehicles for OVs in pre-clinical mouse models. 
These four therapeutic systems were extensively tested till date as cell mediated 
therapeutics. Apart from these systems several other groups used cells as delivery vehicles for 
nanoparticles (gold nanoparticles/targeted photothermal ablation[53], liposomes/drug 
delivery[54]),  radiation therapy (sodium iodide symporter/ 
131
I) [55] and photodynamic therapy 
[56]. There are several other studies that used dendritic cells, T-cells, B-cells and other immune 
cells for immune based cancer therapy (Adoptive cellular therapy)[57]. 
 Magnetic hyperthermia as a cancer treatment 
 Hyperthermia  
Temperature is one of the essential factors that controls cell survival. Changes in 
temperature can cause structural modifications in cells and higher temperatures were known to 
be toxic. Hyperthermia (HT) is a therapeutic approach to treat cancer by exposing tumors to 
lethal temperatures resulting in changing the physiology of cancer cells finally leading to 
apoptosis or necrosis [58, 59]. Side effects caused by hyperthermia are less compared to other 
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cancer treatments, because of tumor tissues and cancer cells susceptibility to thermal toxicity 
[60]. HT has been shown to improve the prognosis of different cancers when used in 
combination with other therapies [61-69]. In several ways HT treatment can be administered 
such as hot water treatment, microwave, radiofrequency, ultra sound, and alternating magnetic 
field (AMF) based Magnetic hyperthermia and each of these treatment has its own 
limitations[59]. In addition to this, the type of heat administration may vary: it will be either 
local, regional (at a specific place), or whole body hyperthermia [58, 70]. 
Heat-induced changes in cancer cells leads to either apoptosis or necrosis in cancer cells 
[71]. If cells are exposed to 40-43˚C -apoptosis results, while temperatures greater than 45˚C 
cause necrosis and again it depends on the exposure time [58]. Lipid bilayer and membrane 
bound ATPases are the least thermally stable components and are most responsible for heat 
induced tissue necrosis [71]. Increases in temperature will also cause effects such as organelle 
changes, changes in protein conformation, heat shock protein (HSP) synthesis, and DNA and 
RNA degradation [71]. Cell death pathways involved in HT include mitochondria-mediated 
apoptosis, ER-mediated apoptotic pathways, and necrosis [58, 71]. Exposure to heat increases 
blood flow to the tumors, which improves tissue oxygenation and increases radio sensitivity [72]. 
In the same way, drug concentration will be less in insufficiently perfused tumors; by increasing 
the blood flow, HT increases the drug concentration in tumors [58]. Chemotherapy combined 
with HT has showed improved results in clinical trials [63, 66, 68]. To a certain point, 
hyperthermia causes cells to overexpress heat shock proteins (HSPs), thus helping cells to 
recover from the temperature-induced damage by repairing proteins, synthesizing enzymes that 
prevent protein aggregation, and degrading severely damaged proteins [73]. But above a 
threshold temperature increase, inhibition of HSP synthesis occurs [74]. HSPs released from 
necrotic cancer cells will have attached tumor specific antigens, and shown to aid in the innate 
and adaptive immune response against tumors [75, 76]  
Magnetic hyperthermia (MHT)  
Magnetic nanoparticles (MNPs) based Magnetic hyperthermia treatment (MHT) became 
a major temperature-based treatment modality because of the number of advantages compared to 
other hyperthermia treatments [59]. When MNPs are exposed to alternating magnetic field 
(AMF) they convert the magnetic energy into thermal energy and increases the temperatures in 
their surroundings [77-79] Heat generation depends on the frequency, amplitude, and time 
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exposed to AMF and on Curie temperature, Specific Absorption Rates (SAR), shape, size, 
dispersity (mono or poly), and type of MNPs [59, 80]. When exposed to AMF, MNPs cause heat 
generation either by hystersis loss or Neel-Brownian relaxation and it depends on the size of 
MNPs [81]. If the particles are large (multi-domain particles), they will generate heat by 
hysteresis loss, while small size particles (single domain particles) generate heat by Neel –
Brownian relaxations [81]. In multi-domain particles hysteresis loss (due to the movement of 
domain walls) contributes to heating, in single domain particles Neel relaxation (random flipping 
of spin) and Brownian motion (rotation of entire particles) generates heat [81, 82].  The 
transition between the two mechanisms occurs between 5-12 nm for various materials, but it also 
varies with frequency [83]. 
Among MNPs, super paramagnetic nanoparticles have more heat generating capacity 
(more SARs) [59, 80, 84]. Super paramagnetic Iron oxide MNPs are commonly used for MHT 
because of their biodegradability, low toxicity, and higher SAR values [59, 85]. Apart from 
MHT, MNPs have different uses in biomedicine like drug delivery, gene delivery, stem cell 
tracking, MRI, biosensing, cell isolation, cellular proteomics [59, 86].Several research groups 
have conducted preclinical studies in animal tumor models by directly injecting MNPs into 
tumors and observed tumor attenuation [59, 80, 87, 88]. This technique works in case of tumors 
which are hard to operate and accessible to inject MNPs, but the main problem in cancer patients 
is metastatic deep disseminated tumors that are smaller in size. In majority of clinical cases, 
clinicians will not have access to these tumors to inject MNPs directly into them for MHT 
treatment and sometimes these metastatic tumors are not even identifiable with available 
diagnostic techniques. Systemic intravenous administration of MNPs followed by AMF exposure 
showed tumor attenuation or increased survival in mouse models [89, 90], but these articles 
reported accumulation of MNPs in other healthy tissues which can cause severe side effects. 
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 Abstract 
Localized magnetic hyperthermia as a treatment modality for cancer has generated 
renewed interest, particularly if it can be targeted to the tumor site. In this present study, tumor-
tropic neural progenitor cells (NPCs) ability to utilize as cell delivery vehicles for achieving 
preferential accumulation of core/shell iron/iron oxide magnetic nanoparticles (MNPs) within a 
mouse model of melanoma was examined. Aminosiloxane−porphyrin functionalized MNPs 
loading efficiency, cellular level toxicity was examined on NPCs and transplanted NPCs loaded 
with this cargo into mice with melanoma. NPCs were efficiently loaded with core/shell Fe/Fe3O4 
MNPs with minimal cytotoxicity; the MNPs accumulated as aggregates in the cytosol. The NPCs 
loaded with MNPs could travel to subcutaneous melanomas, and after A/C (alternating current) 
magnetic field (AMF) exposure, the targeted delivery of MNPs by the cells resulted in a 
measurable regression of the tumor volume. Temporary tumor attenuation was observed for a 
short time (24 h) after the last of three AMF exposures. 
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 Introduction 
Hyperthermia has been a cancer therapy method for decades. Tumors have shown 
increased susceptibility to thermal toxicity versus healthy tissue due to their increased rate of cell 
cycling, increased hypoxia, poor fluid exchange and increased acidity [70, 91]. Whole body 
hyperthermia is an easy way to take advantage of this differential toxicity to treat cancer. 
Unfortunately, ‘extreme’ whole body hyperthermia (>41.5°C), which elevates core temperatures 
to the level where direct thermal toxicity is observed, can cause severe side effects, which may 
limit its usefulness [92-96]. Fever-level whole body hyperthermia (~39-41°C) can mitigate many 
of these side effects and has potential to be an effective cancer treatment, but this lower heat 
level is thought, primarily, to stimulate the immune system and the benefits of direct thermal 
toxicity are reduced [97, 98]. Generating localized ‘extreme’ hyperthermia at the cancer site 
could alleviate many of the side effects associated with whole body hyperthermia while still 
taking advantage of the thermal susceptibility of tumors.  
One particularly promising method for generating localized hyperthermia is using 
magnetic nanoparticles (MNPs) to absorb energy from alternating magnetic fields (AMF) and 
converting this energy into heat. This method is promising because the body is extremely 
permeable to AMF, which itself produces no known effects in the body [99, 100]. For magnetic 
hyperthermia, super paramagnetic iron oxide nanoparticles are usually used for absorbing the 
magnetic field[79]. In most of the pre-clinical and clinical studies, MNPs were directly injected 
into the tumors and exposed to AMF to achieve hyperthermic temperatures in tumors [87, 88, 
101].  
MHT of disseminated or deep tumors is currently complicated because it is difficult to 
target MNPs to the tumors. To date, most reports of localized magnetic hyperthermia have 
described the direct tumor injection of milligram amounts of magnetic materials [87, 88, 90]. 
Many attempts have been made to increase localization of various kinds of nanoparticles, 
including magnetic nanoparticles for imaging or therapy, to tumors. For example, particles have 
been tagged with antibodies recognizing tumor-specific epitopes [102, 103] or peptides binding 
to receptors on tumor cells or neo-vasculature [104, 105]. In some cases, limited success has 
been realized after antibodies or other ligands have been attached to MNPs [106]. However, 
further improvements in tumor targeting are needed. Both direct killing effects and sensitization 
to other treatment modalities with MHT treatment are dependent on distribution of MNPs in 
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tumors and duration of temperature elevation during AMF exposure [107, 108]. Bi-magnetic 
particles (10−40 nm) are able to generate substantial heat within a magnetic field of low strength 
and frequency. The bi- magnetic nanoparticles (MNPs) used in this present study have a strong 
ferromagnetic iron core, which produces high temperatures with short AMF exposure [78],a 
magnetic iron oxide shell for MRI [109], an aminosiloxane-anchored oligoethylene glycol stealth 
coating, and chemically attached porphyrins (TCPP, tetra-4-carboxyphenyl porphyrin) (Figure 
2-1A).  
Tumor-homing cells have been used as delivery vehicles for targeted gene therapy for 
preclinical models of cancer [9, 12, 47, 110-116]. In addition to being used to deliver genes, 
bone marrow stem cells have been loaded with iron oxide nanoparticles and used to target 
murine lung cancer for MRI [117]. Neural progenitor cells (NPCs) or Neural stem cell (NSCs) 
are known to have tumor-tropic properties, and many groups have successfully used NPCs as 
therapeutic delivery vehicles to tumors [10, 12, 118-121].  
By considering these rationales we hypothesized that tumor targeted MHT can be 
achieved by delivering MNPs through NPCs on mouse melanoma tumors. To test this 
hypothesis, first Aminosiloxane-coated Fe/Fe3O4 core/shell bi magnetic nanoparticles (MNPs) 
toxicity, loading efficiency was analyzed on C17.2 neural progenitor cells. Temperature increase 
in MNPs loaded NPCs after AMF exposure was demonstrated by using in vitro models. 
Intravenously injected MNPs loaded NPCs homed to subcutaneous B16-F10 melanoma tumors 
after 4 days of transplantation. Mild melanoma tumor volume decrease was observed after three 
10mins AMF exposures on these mice (not statistically significant). Apoptosis assay on AMF 
treated tumors revealed increased apoptosis positive cells (qualitative observation). Suggesting 
that tumor homing cells can be used as delivery vehicles for tumor targeted MHT treatment. 
 Materials and Methods 
  TCPP-Linked Stealth-Coated Fe/Fe3O4/ASOX Nanoparticles 
Aminosiloxane-coated Fe/Fe3O4 core/shell nanoparticles (MNPs) were synthesized by 
NanoScale Corporation (Manhattan, KS). Dopamine stealth coating and TCPP targeting units 
attachment were performed by Stephen Bossmann’s lab. Nanoparticles synthesis and their 
characteristics were explained in detail in Rachakatla et al., 2010 [122] (MNPs schematic picture 
was presented in Figure 2-1A). 
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Tissue Culture of C17.2 Neural Progenitor Cells and B16-F10 Melanoma Cells 
B16-F10 melanoma cells were purchased from ATCC (Manassas, VA) and maintained in 
Dulbecco’s modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 
10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO) and 1% penicillin/streptomycin 
(Invitrogen) at 37 °C in a humidified atmosphere containing 5% carbon dioxide. 
C17.2 neural progenitor cells (NPCs) and firefly luciferase expressing C17.2 neural progenitor 
cells (NPC-Flucs) were a gift from V Ourednik (Iowa State University). Originally developed in 
Evan Snyder’s lab [123], these cells were maintained in DMEM supplemented with 10% FBS 
(Sigma-Aldrich), 5% horse serum (Invitrogen), 1% glutamine (Invitrogen), and 1% 
penicillin/streptomycin (Invitrogen). 
 Cytotoxicity of MNPs on Neural Progenitor Cells and B16-F10 Cells 
Potential cytotoxic effects of MNPs were studied by incubating C17.2 NPCs and B16-
F10 melanoma cells in different concentrations of MNPs (as determined by iron content). NPCs 
and B16-F10 cells were plated at 50,000 cells/cm
2
 and incubated overnight with their respective 
media containing MNPs at concentrations of 5, 10, 15, 20, or 25 μg/mL iron. After incubation, 
medium was removed and cells were washed twice with DMEM. Cells were lifted via 
trypsinization, and mixed with collected medium and washed DMEM. Live and dead cell 
numbers were counted via hemocytometer with Trypan blue staining. This method allows 
counting of viable (colorless) and nonviable (blue stained) cells since only the dead cells allow 
the blue stain into the cell.  
 Prussian Blue Staining on NPCs 
The loading efficiency of MNPs into NPCs was assessed using Perl’s Prussian blue stain 
kit (Polysciences, Inc., Warrington, PA). After overnight incubation in NPC medium containing 
25 μg/mL iron in MNPs, NPCs were washed twice with DMEM and PBS and fixed with 4% 
glutaraldehyde for 10 min. Fixed NPCs were incubated in a solution containing equal amounts of 
4% potassium ferrocyanide and 4% HCl for 20 min. After 20 min incubation, NPCs were 
washed twice with 1× PBS and counterstained with nuclear fast red solution for 5 min. Images 
were captured using a Zeiss Axiovert 40 CFL microscope (New York) and a Jenoptik ProgRes 
C3 camera (Jena, Germany). 
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 Loading Strategy of MNPs and Determination of Iron Amounts 
The loading efficiency of NPCs with various iron concentrations of MNPs was 
determined spectrophotometrically using a Ferrozine based iron estimation method [124]. For 
this method, cells were incubated overnight with NPC medium containing different 
concentrations of MNPs and then washed twice with DMEM and 1× PBS. Cells in medium 
without MNPs were used as controls. All NPCs (control cells and cells loaded with various iron 
concentration of MNPs) were trypsinized, counted, and centrifuged, and total cells were 
resuspended in 2 mL of distilled water. Cells were then lysed by adding 0.5 mL of 1.2 M HCl 
and 0.2 mL of 2 M ascorbic acid and incubating at 65−70 °C for 2 h. After 2 h, 0.2 mL of 
reagent containing 6.5 mM Ferrozine (HACH, Loveland, CO), 13.1 mM neocuproine (Sigma-
Aldrich, St. Louis, MO), 2 M ascorbic acid (Alfa Aesar, Ward Hill, MA), and 5 M ammonium 
acetate (Sigma-Aldrich, St. Louis, MO) was added and incubated for 30 min at room 
temperature. After 30 min, samples were centrifuged at 1000 rpm for 5 min, and supernatant 
optical density was measured by a UV−vis spectrophotometer (Shimadzu, Columbia, MD) at 
562 nm. A standard curve was prepared using 0, 0.1, 0.2, 0.5, 1, 2, and 5 μg/mL ferrous 
ammonium sulfate samples. Water with all other reagents was used as a blank. From the standard 
curve, iron concentration in cell samples was determined. Iron concentration per single cell was 
estimated by dividing the iron amount in each cell sample by the total number of cells in that 
sample assuming all the cells were loaded with equal amount of MNPs. 
 AMF-Induced Temperature Changes In Vitro 
To verify the temperature increase by NPCs loaded with MNPs in a simulated matrix 
environment, NPCs were loaded overnight with MNPs equivalent to 15 μg/mL Fe. After 
incubation, cells were washed twice with DMEM and twice with 1× PBS to remove free MNPs. 
Cells were lifted with 0.1% trypsin-EDTA, and 1 × 10
6
 cells were pelleted by centrifugation in 2 
mL centrifuge tubes; 1.5 mL of 4% agarose solution was added on top of the cell pellet to make a 
solid matrix. Agarose centrifuge tubes containing pelleted NPCs without MNPs were used as 
negative controls and were made as described above. The experiment was conducted in 
triplicate. Before each tube was exposed to AMF, two optical probes (Neoptix, Quebec, Canada) 
were inserted into the tube: one at the pellet, and the second one at the middle of the agarose 
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solid. Tubes were exposed to AMF for 10 min, and the temperature difference over time was 
measured by the probes. 
 Evaluation of Selective Engraftment of NPCs and Magnetic Hyperthermia 
Female, 6−8 week old, C57BL/6 mice were purchased from Charles River Laboratories 
(Wilmington, MA). Mice were held for 1 week after arrival to allow them to acclimate. Mice 
were maintained according to approved IACUC guidelines in the Comparative Medicine Group 
facility of Kansas State University. All animal experiments were conducted according to these 
IACUC guidelines. On day 0, 3.5 × 10
5
 B16-F10 melanoma cells were injected subcutaneously 
into 45 C57BL/6 mice, day-4 after tumor cells injection tumor diameters were measured and 
mice were stratified into four groups (unbalanced design). On day 5, 1 × 10
6
 NPCs loaded with 
MNPs at 20 μg/mL iron concentration were injected intravenously to two groups (NPC(Fluc)-
MNP, group III and NPC(Fluc)-MNP+AMF, group IV); simultaneously NPC(Fluc)s were 
injected to group II and 1x PBS was injected into group I (Figure 2-5). On the ninth, 10th, and 
11th days after tumor inoculation, group IV mice with NPC-loaded MNPs were exposed to AMF 
for 10 min daily using an alternating magnetic field apparatus (Superior Induction Company, 
Pasadena, CA). The frequency is fixed (366 kHz, sine wave pattern); field amplitude is 5 kA/m. 
Tumor diameters were measured using a caliper on days 8, 10,12,13,14 and 15; tumor volumes  
were calculated using the formula 0.5a × b
2
, where a is the larger diameter and b the smaller 
diameter of the tumor (the above formula assumes tumor is in ellipsoidal shape). All of the mice 
were then euthanized on day 15, tissues were collected and tumor weights were measured.   
 Histological Analysis 
All mice were sacrificed 15 days after tumor inoculation by CO2 inhalation and cervical 
dislocation. Tumor, lung, liver, and spleen were snap-frozen in liquid nitrogen for histological 
analysis. Tissues were sectioned on a cryostat (Leitz Kryostat 1720, Germany) at 8−10 μm and 
used for histological studies. Prussian blue staining was performed on these sections using Perl’s 
Prussian blue stain kit to identify NPCs loaded with MNPs. Apoptotic cell detection in the tissue 
sections was determined using the DeadEnd fluorometric terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) system (Promega Corporation, Madison, WI), as per the 
manufacturer’s protocol. 
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 Protein Preparation for Two-Dimensional Electrophoresis (2-DE) 
To identify protein expression differences between tumors from mice receiving AMF 
after IV saline injection or after IV NPC-MNP injection, 3.5 × 10
5
 B16-F10 melanoma cells 
were injected subcutaneously into two mice. On day 5, 1 × 10
6
 NPCs loaded with MNPs at 20 
μg/mL iron concentration were injected intravenously into one mouse; simultaneously, saline 
was injected into the other mouse. On days 9, 10, and 11, tumors were exposed to AMF. On day 
11, mice were euthanized and tumors were collected immediately after AMF exposure. 
Total protein was prepared from the tumors for use in two-dimensional gel electrophoresis (2-
DE) analysis. The following protein isolation protocol was used [125]. Briefly, melanoma tissues 
were homogenized using a Pellet Pestle Mortar (KONTES, Vineland, NJ) in the presence of 0.5 
mL of lysis buffer (8 M urea, 2 M thiourea, 4% 3-cholamidopropyldimethylammonio-1-
propanesulfonate (CHAPS), 100 mM dithiothreitol (DTT), 25 mM Tris-Cl, and 0.2% ampholyte 
(pH 3−10) (Amersham Pharmacia Biotech, Piscataway, NJ). The supernatant was collected and 
then precipitated using 2 volumes of ice-cold acetone. The final protein pellet was dissolved in 
100 μL of the sample buffer (8 M urea, 2 M thiourea, 4% CHAPS, 100 mM DTT, 25 mM Tris-
Cl, and 0.2% ampholyte (pH 3−10)). Protein concentrations were determined using a reducing 
agent-compatible and detergent-compatible protein assay kit (Bio-Rad, Hercules, CA). 
 2-DE Analysis 
Fifty micrograms of total protein was resolved at 20 °C in the first dimension by 
isoelectric focusing (IEF) in an IEF cell system (Bio-Rad, Hercules, CA) using 7 cm long, pH 
3−10, precast immobilized pH gradient strips (Bio-Rad). The IEF parameters were 250 V for 15 
min, followed by 4000 V for 5 h. At the end of the IEF, the strips were equilibrated sequentially 
for 10 min each in 1 mL of equilibration buffer I (375 mM Tris-HCl [pH 8.8], 6 M urea, 2% 
sodium dodecyl sulfate (SDS), 2% DTT) and buffer II (375 mM Tris-HCl [pH 8.8], 6 M urea, 
2% SDS, 2.72 mg of iodoacetamide/mL, 0.001% bromophenol blue). Subsequently, second-
dimension SDS-polyacrylamide gel electrophoresis analysis was performed on the strips in a 
Mini-PROTEAN Tetra system by using 12% polyacrylamide gels (Bio-Rad) for 40 min at 200 V 
at room temperature in a 50 mM Tris-glycine buffer. The 2-DE resolved gels were stained by 
using a Biosafe Coomassie G-250 kit (Bio-Rad). Coomassie stained gels were digitalized by 
using an HP Scanjet 7400c scanner (Hewlett-Packard, Houston, TX). 
16 
 
 Matrix-Assisted Laser Desorption Ionization (MALDI)-TOF MS Analysis of 
Melanoma Tissues Treated with AMF and AMF with NSC-MNP Proteins 
After resolution by 2-DE, proteins from melanomas from mice treated with AMF and 
MNP-NPC+AMF were picked individually from Coomassie blue stained gels using 
PROTEINEER spII with sp-Control 3.0 software (Bruker Daltonics, Bremen, Germany) 
according to the manufacturer’s protocol. Coomassie blue stained proteins were digested as 
described by Shevchenko et al [125]. An aliquot of in-gel-digested solution was mixed with an 
equal volume of a saturated solution of 1 μL of 2,5-dihydroxybenzoic acid (DHB) in 50% 
aqueous acetonitrile, and 1 μL of mixture was spotted onto a target plate. Protein analysis was 
performed with a Bruker UltraFlex II MALDI-TOF using MTP AnchorChip with 384 matrix 
spots. MALDI-TOF spectra were externally calibrated using a combination of nine standard 
peptides: bradykinin 1-7 (757.39 Da), angiotensin II (1046.54 Da), angiotensin I (1296.68 Da), 
neurotensin (1672.91 Da), renin substrate (1758.93 Da), ACTH clip 1-17 (2093.08 Da), ACTH 
clip 18-39 (2465.19 Da), ACTH clip 1-24 (2932.58 Da), and ACTH clip 7-38 (3657.92 Da), 
spotted onto positions adjacent to the samples. Protein identification was carried out by 
automatic comparison of experimentally generated monoisotopic values of peptides using 
MASCOT with a tolerance of 0.5−0.3 Da and 0−1 missed cleavage, and oxidation of methionine 
was allowed. 
 Statistical Analysis 
Statistical analyses were performed using WinSTAT (A-Prompt Corporation, Lehigh 
Valley, PA). Cytotoxicity of MNPs data were analyzed by using one way analysis of variance 
(ANOVA) with least significant difference (LSD) multiple comparisons. Iron concentration per 
single NPC cell (Loading efficiency of MNPs) was estimated by using iron standards as linear 
model and estimated iron concentration per single NPC cells again modeled by using linear 
model. AMF induced temperature changes and overall differences in tumor volumes between all 
in vivo groups were analyzed by using Repeated measures ANOVA. Tumor weights were 
analyzed by using one way ANOVA. A p value less than 0.05 was considered as significant for 
one way ANOVA and repeated measures ANOVA and significance for LSD post hoc multiple 
comparisons was set at p < 0.05. All of the tumor volume data are represented as mean ± 
standard error (SE) on graphs. 
17 
 
 Results  
 Loading Studies of MNPs on NPCs 
MNPs efficiently loaded into NPCs. After Prussian blue staining, MNPs were detected in 
NPCs as blue staining material (Figure 2-1B). Transmission electron microscope (TEM) images 
of NPCs showed loaded MNPs as aggregates in the cell cytoplasm (Figure 2-1C). Close 
examination of additional TEM images revealed that in some images the aggregates were 
surrounded by fragmented unit membrane, indicating they were possibly in an endosomal 
compartment (Figure 2-1D). In most images, they did not appear to be so enclosed. On the basis 
of these results, there is possibility that the MNPs are taken up via the LDL receptor and traffic 
in the endosomal−lysosomal system but cause endosomolysis with subsequent release of MNPs 
into the cytosol (need further confirmation). The loading efficiency of MNPs into NPCs 
increased with increasing concentration of MNPs in medium. The highest concentration of 
1.6±0.2 pg of iron per cell was identified in cells incubated with medium containing 25 μg/mL 
iron (Figure 2-2). 
 Cytotoxicity of MNPs on Neural Progenitor Cells and B16-F10 Cells 
MNP toxicity was tested based on iron concentration in MNPs. Media containing various 
iron concentrations of MNPs were added to NPCs and B16-F10 cells and incubated overnight. 
The toxic effect of these MNPs increased with increasing iron concentration. Cell viability 
assessment for varying concentrations of MNPs on NPCs and B16-F10 cancer cells is shown in 
Figure 2-3A and B respectively. NPCs tolerated the MNPs well through 20 μg/mL iron 
concentration (Figure 2-3A), so this MNPs concentration was used for subsequent experiments. 
However, the B16-F10 cell number was decreased upon exposure to only 10 μg/mL iron 
concentration (Figure 2-3B). Difference in cytotoxicity of these MNPs on NPCs and B16F10s 
could be because of differences in growth rates of the used cell lines. 
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 AMF-Induced Temperature Changes In Vitro 
Temperature increase over time was compared between NPC controls and MNP-loaded 
NPCs (NPCs-MNPs) (Figure 2-4). There was a ~2.6 °C increase between control and MNP-
loaded cells (not significant) at cell pellet position after 10 min of AMF exposure. There is no 
identifiable difference in temperature in the middle of agarose between NPCs and NPCs –MNPs 
after 10 min of AMF exposure suggesting heat generated at pellet position is not distributing 
through agarose.  
 NPC-MNP and A/C Magnetic Field Effect on Melanoma 
Substantial numbers of MNP-loaded NPCs were identified in tumor sections at the 
borders of tumors after 4 days after IV administration (Figure 2-7D). To test the hypothesis that 
administration of NPCs loaded with MNPs followed by AMF application would reduce the 
tumor burden, NPC (Fluc)-MNPs were injected intravenously into melanoma-bearing mice. 
Tumor volume comparisons are graphed in Figure 2-6A. Although tumor volume differences 
between groups were not significant overall (Repeated measures ANOVA), NPC 
(Fluc)+MNP+AMF group tumor volume has mild regression trend after day-10 compared with 
other groups (Figure 2-6A). After 15 days, all of the mice were euthanized and tumor weights 
were measured. There is no significant difference between tumor weights of different groups 
(Figure 2-6B). There are no prussian blue positive cells in tumor tissues from mice subjected to 
AMF exposure, evaluated at the end of the experiment ( Figure 2-7C). This absence may indicate 
that the NPCs perished and released their cargo, which was subsequently removed from the site 
by phagocytic cells. 
To find potential mechanisms of this mild tumor volume attenuation, tumor tissues were 
collected 24 h after the last AMF treatment on some of the mice. There was an increase in the 
apoptotic index in the NPC-MNP IV transplanted group after three rounds of AMF, indicating 
that the targeted magnetic hyperthermia had a measurable effect on cell viability 24 h after the 
last treatment (Figure 2-7E ). This corresponds to the time at which subcutaneous tumor volumes 
in the group receiving NPCs loaded with MNPs and subsequent AMF were less than tumor 
volumes in any of the other groups (Figure 2-6A- not significant). Hence, apoptosis appears to be 
a mechanism involved in reduced tumor volumes. 
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 Proteomic Analysis 
To further investigate the mechanisms tumors were excised from mice receiving either 
NPC-MNP followed by AMF or PBS followed by AMF. Total protein was extracted from these 
tumors, and the extracted proteins were separated using 2-D gel electrophoresis. Gel spots 
representing 12 proteins expressed differentially in the 2 mouse groups were pinpointed using 
the MASCOT identification search software for identifying peptide mass fingerprinting (PMF). 
These protein spots are noted in Figure 2-8. We attempted to identify each of the proteins 
comprising the 12 differentially expressed spots using MALDI-TOF mass spectrometry. 
Identified proteins are listed in Table 2-1. As can be seen, phosphoglycerate kinase 1 (PGK1) 
and neurotensin receptor 1 protein were much more highly expressed in tumors from the mice 
receiving intravenous NPC-MNP followed by AMF treatment than in the PBS+AMF controls. 
The group receiving NPCs+ AMF alone was not included in this comparison because Prussian 
blue staining failed to identify any intact NPCs in NPC-MNP treated tumor tissue at the end of 
the experiment, indicating that the NPCs had been killed at some point by the A/C magnetic field 
exposure. Thus, it is unlikely that any differences in protein levels are due to the presence of the 
delivery cells. Also, it is unlikely that the NPCs, which are a minor population, could secrete 
enough protein to register as a difference to be picked as spots on the second dimension gels 
even had they survived. Of the seven protein spots found in the treated group but not the saline 
group (see Table 2-1), one candidate protein identified that could potentially exert an antitumor 
effect is PGK1, which is anti-angiogenic when overexpressed in some tumors [126]. However, 
overexpression of PGK1 in prostate cancer has been shown to facilitate tumor growth [127]. On 
the other hand, there were five protein spots present in the saline control group that were not 
present in the treated group. One of these was TNF receptor-associated factor 5 (TRAF5), which 
is known to activate NF-κB [128]. Another, biliverdin reductase B, also increases NF-κB 
expression [129]. NF-κB is a central player in the transition to a more invasive state in many 
tumors [130]. Biliverdin reductase B was identified as a specific protein marker in 
microdissected hepatocellular carcinoma [131], elevated in methotrexate-resistant colon cancer 
cells [132], and is induced in renal carcinoma [133]. Hence, it possible that down-regulation of 
these genes could have been a factor in reduction of tumor size. While preliminary, these 
findings provide the background for further investigation to reveal potential mechanisms of 
tumor attenuation by AMF after targeted delivery of MNPs by tumor-tropic stem cells. 
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 Discussion 
This is the first report in literature showing that tumor-tropic cells loaded with MNPs ex 
vivo and administered intravenously can result in mild regression of preclinical tumors after A/C 
magnetic field exposure. In a previous report, we showed that even microgram amounts of these 
bi magnetic MNPs given intra-tumorally or intravenously could reduce subcutaneous melanomas 
[90]. However, Prussian blue staining for iron was much more pronounced in the lungs and liver 
than in the work reported here. Thus, an advantage of the cell-based delivery of the MNPs seems 
to be that it avoids agglomeration of MNPs in the reticulo-endothelial (mononuclear phagocytic) 
system. 
Although the probable accumulation of MNPs reported here is low compared to most 
reported tumor accumulations in vivo, the iron core of the MNPs used in this work may allow 
smaller amounts of the MNPs to respond to an A/C magnetic field in vivo than would be 
expected for iron oxide MNPs. Based on in vitro loading efficiency studies (Figure 2-2) the 
amount of iron (represents MNPs amount) present in single MNPs loaded cell is 1pg (with 
20µg/mL iron MNPs incubation), so the amount transplanted with 1 × 10
6
 NPCs is ~1µg of iron 
MNPs. Temperature increase observed with 1 × 10
6
 MNP loaded NPCs is ~2.6 °C (Figure 2-4), 
which is more of mild hyperthermia temperature than increases observed in other MHT pre-
clinical studies. Again for in vitro model used here to identify the AMF induced temperature, all 
the MNPs loaded NPCs were taken as pellet form, which is different from the NPCs distribution 
observed in tumors ( Figure 2-7D). Therefore, “hot spots” featuring a high temperature may exist 
during A/C magnetic heating, which can lead to local damage of the cells at multiple locations, 
even when the total temperature of the tumor tissue is not significantly enhanced (need further 
studies to confirm this hypothesis).   
It is possible that mild tumor attenuation effect observed in present study could be by 
other factors in addition to A/C magnetic field exposure after MNP delivery to tumor by NPCs. 
Cytokines released by the NPC-MNP after mild hyperthermia may helped in this mild 
attenuation; a recent report indicates that conditioned medium from heat-treated mesenchymal 
stem cells significantly inhibited proliferation of cancer cells in vitro [134, 135]. Another factor 
that could enhance the antitumor effect of mild to moderate regional hyperthermia in vivo is 
stimulation of the innate immune response. Recently, for example, it has been shown that 
elevating local tumor temperature to only 41−43 °C is sufficient to activate natural killer (NK) 
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cells [136].NK cells are part of the innate immune system and are potent tumor-lytic agents when 
activated [137]. Kubes et al. showed that high numbers of activated monocytes with increased 
cytotoxic effector function were recruited into B16-F10 melanoma-bearing mice after mild local 
microwave hyperthermia [138]. 
MHT treatment potentiality depends on the distribution of MNPs in tumors, amount of 
MNPs present in tumors during AMF exposure, exposure time to AMF[107]. By, loading high 
amounts of MNPs in delivery cells and by repeated injections of MNPs loaded cells; increased 
accumulation of MNPs can be achieved in tumors. Increasing exposure time to AMF also can 
increase the targeted MHT treatment ability. In present study, injected NPCs were observed only 
at the borders of tumor ( Figure 2-7D) which can limit the overall tumor heating. Tumor homing 
cells that can distribute all over the tumor can potentiate the effect observed in this present study. 
By considering the points explained in above discussion – Amount of MNPs in delivery cells, 
Number of cells for treatment, AMF exposure time next hypothesis was proposed and tested in 
Chapter 2 - . 
 Conclusions 
In conclusion, These studies show here that (1) NPCs efficiently load with core/shell 
Fe/Fe3O4 bi-magnetic nanoparticles (MNPs); (2) the MNPs accumulate with time as aggregates 
in the cytosol; (3) the MNPs cause minimal toxicity in those cells; (4) NPCs loaded with MNPs 
travel to subcutaneous melanomas; (5) after A/C magnetic field exposure, the targeted delivery 
of MNPs by the cells results in a mild regression of the tumor volumes; and (6) this treatment 
results in apoptosis of cancer cells and alters the tumor proteome.  
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Figure 2-1 Loading studies of MNPs on NPCs 
 A. Schematic picture of TCPP-targeting units containing Fe/Fe3O4/Aminosilaxane/stealth 
nanoparticles, B. Bright-field image of NPCs loaded with MNPs showing positive Prussian blue 
staining for the presence of iron and counterstained with nuclear fast red (magnification 20x), C. 
TEM image of NPC loaded with MNPs (arrows) (magnification 30000x), D.TEM picture 
showing MNPs (black arrow) aggregate surrounded by membrane fragments (white arrow) 
(magnification 70000x).  
23 
 
y = 0.0632x - 0.07 
R² = 0.8231 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
-2 3 8 13 18 23 28
Ir
o
n
 c
o
n
ce
n
tr
a
ti
o
n
 p
er
 c
el
l 
(i
n
 p
ic
o
 g
ra
m
s)
 
Iron concentration in MNP 
Figure 2-2 Loading efficiency of MNPs on NPCs 
Iron concentration per NPC cell incubated with various concentrations of MNPs containing 
medium (Pearson correlation coefficient- 0.9, one-sided significance- <0.05). 
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Figure 2-3 Cytotoxicity of MNPs on Neural progenitor cells (NPCs) and B16F10 melanoma 
cells 
A. In vitro cell viability of NPCs cultured in medium containing increasing concentrations of 
MNPs (One way ANOVA- <0.1, LSD at 0.05 significance level 25µg/mL vs all other groups 
except 20µg/mL), B. In vitro cell viability of B16-F10s cultured in medium containing 
increasing concentrations of MNPs (One way ANOVA- <0.05, LSD at 0.05 significance level 
control vs all other groups except 5µg/mL; 5µg/mL vs 15, 20, 25 µg/mL; 10µg/ mL vs 20, 25 
µg/mL). 
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Figure 2-4 Alternating magnetic field (AMF) induced temperature changes in vitro 
Temperature measurements after AMF of NPCs loaded with MNPs and NPC controls at the 
pellet and in the agarose solid. (Repeated measures ANOVA- not significant). 
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Figure 2-5 Experimental design for Magnetic nanoparticles (MNPs) loaded Neural 
progenitor cells (NPCs) mediated Magnetic hyperthermia treatment (MHT) 
A. Days schedules of NPC-MNP and A/C Magnetic field effect on Melanoma experiment, B. 
Groups and number of mice in each group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Number Group Sample size 
I PBS 11 
II NPC(Fluc) 10 
III NPC(Fluc)+MNP 11 
IV NPC(Fluc)+MNP+AMF 13 
   
   
 
A 
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Figure 2-6 Neural progenitor cells (NPCs) loaded with MNPs and A/C Magnetic field effect 
on melanoma 
A Calculated tumor volume comparison between different groups from day-8 to day-15, data 
were analyzed by using repeated measures ANOVA (not significant) B. Tumor weights 
comparison between different groups on day-15, data were analyzed by using one way ANOVA 
(not significant). 
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 Figure 2-7 Histological analysis of mouse tissues 
 (A-D) Prussian blue stained tissue sections, counterstained with nuclear fast red of melanoma 
tumor bearing mice which received NPC-MNP followed by AMF treatment: liver(A), lung(B), 
tumor(C); note the absence of Prussian blue stained NPCs in tumor sections. Prussian blue 
stained NPCs loaded with MNPs in tumor section of mouse which received NPC-MNP but no 
AMF treatment (D). (E,F) TUNEL assay: green apoptotic cells in tumor- bearing mouse with 
NPC-MNP+AMF (E) compared to few apoptotic cells in tumor-bearing mice with saline only 
treatment (F).  
 
 
 
 
 
  
29 
 
Figure 2-8 Two-dimensional gels of melanoma tissues from mice treated with PBS + AMF 
or NPCs-MNP + AMF 
Tumor samples from mice received PBS+AMF (A) and NPCs-MNP+AMF (B) were harvested 
and processed for the first dimension, electrophoretically separated on 12% acrylamide gels and 
stained with Biosafe coomassie G-250 stain. Numbers with arrowhead lines refer to protein spots 
identified by MALDI-TOF analysis. 
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Table 2-1 Proteins of Melanoma tumor treated with PBS+AMF and NPCs-MNP+AMF, 
analyzed by MALDI-TOF 
  
Spot 
number 
  
    
  Protein identification 
GenBank 
Numbers 
Theoretical 
MW (Da) 
pI Sequence 
coverage 
(%) 
Saline + AMF 
1 TNF receptor-associated 
factor 5 
gi|6755867 65679 7.71 14 
2 Aste1 protein gi|68534685 69927 8.31 12 
3 Beta-globin gi|156257677 15823 7.14 78 
4 Biliverdin reductase B gi|21450325 22299 6.49 53 
5 Unnamed protein product gi|74222020 27054 6.90 39 
NPC-MNP + AMF 
6 Zmym1 protein gi|116283425 103513 8.88 10 
7 Neurotensin receptor 1 gi|9055296 47708 9.39 19 
8 Unnamed protein product gi|74211198 54416 10.00 13 
9 Unnamed protein product gi|74211198 51420 9.09 16 
10 Phosphoglycerate kinase 1 gi|70778976 44928 8.02 43 
11 Phosphoglycerate kinase 1 gi|70778976 44928 8.02 53 
12 Similar to Glyceraldehyde-3-
phosphate dehydrogenase 
gi|149252413 34190 8.45 27 
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 Abstract 
Using magnetic nanoparticles to absorb alternating magnetic field energy as a method of 
generating localized hyperthermia has been shown to be a potential cancer treatment. This report 
demonstrates a system that uses tumor homing cells to actively carry iron/iron oxide 
nanoparticles into tumor tissue for alternating magnetic field treatment. Paramagnetic iron/ iron 
oxide nanoparticles were loaded into RAW264.7 cells (mouse monocyte/ macrophage-like cells), 
which have been shown to be tumor homing cells. A murine model of disseminated peritoneal 
pancreatic cancer was then generated by intraperitoneal injection of Pan02 cells. After tumor 
development, monocyte/macrophage-like cells loaded with iron/ iron oxide nanoparticles were 
injected intraperitoneally and allowed to migrate into the tumor. Three days after injection, mice 
were exposed to an alternating magnetic field for 20 minutes to cause the cell-delivered 
nanoparticles to generate heat. This treatment regimen was repeated three times. A survival study 
demonstrated that this system can significantly increase survival in a murine pancreatic cancer 
model, with an average post-tumor insertion life expectancy increase of 31%. This system has 
the potential to become a useful method for specifically and actively delivering nanoparticles for 
local hyperthermia treatment of cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
 Introduction 
Pancreatic cancer is known to be one of the most lethal forms of cancer, with five year 
survival rates of less than 5% [139]. Discovering new methods for successfully treating 
pancreatic cancer is a virtual necessity for combating this disease. Through Chapter-1 Neural 
progenitor cells directed hyperthermia has been successfully demonstrated to cause mild 
attenuation of mouse melanomas (Figure 2-6) [122]. As mentioned previously in Chapter-1, 
Magnetic hyperthermia treatment (MHT) treatment potentiality depends on the distribution of 
Magnetic nanoparticles (MNPs) in tumors, amount of MNPs present in the tumors during 
alternating magnetic field (AMF) exposure, exposure time to AMF[107]. By, loading high 
amounts of MNPs in delivery cells and by repeated injections of MNPs loaded cells; increased 
accumulation of MNPs can be achieved in tumors. Increasing exposure time to AMF also can 
increase the targeted MHT treatment ability. Tumor homing cells that can distribute all over the 
tumor can potentiate MHT treatment effect. By considering the points explained above– Amount 
of MNPs in delivery cells, number of cells per treatment and number of treatments, exposure 
time to AMF present hypothesis was designed. 
Monocytes and macrophages are known to infiltrate tumor sites and thus could act as 
cytotherapeutic drug delivery vehicles [140, 141].  Several recent studies have demonstrated the 
feasibility of delivering therapy to tumors using monocytes or macrophages, including targeting 
liposomes containing fluorescent markers to gastric tumors [54], targeting adenovirus to prostate 
tumors [13], and targeting gold nanoshells to gliomas [142]. Macrophages were known as 
professional phagocytic cells [143] and can engulf high amounts of MNPs compared with non- 
phagocytic cells [144, 145]. 
Here we demonstrate a system that uses monocyte-like tumor homing cells to deliver 
MNPs directly into the tumor tissue. We have demonstrated that RAW264.7 cells 
(monocyte/macrophage-like cells, Mo/Ma, ATCC TIB-71) specifically infiltrate pancreatic 
tumors when injected intraperitoneally (i.p.) without infiltrating other organs. These cells were 
loaded with MNPs in order to deliver the MNPs specifically to the tumor for localized 
hyperthermia. To test this system, a murine model of disseminated peritoneal carcinomatosis of 
the pancreas was generated by injecting Pan02 cells i.p. into C57BL/6 mice [146]. MNPs loaded 
Mo/Ma were then injected and allowed to infiltrate the tumor tissue.  Three days after Mo/Ma 
injection, mice were treated with AMF. This treatment system significantly increased the 
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survival time of mice bearing i.p. pancreatic tumors, with an average lifespan increase post 
tumor injection of 31%.   
Materials and Methods 
 Reagents and Cells 
C57BL/6 mice (11 weeks old) were purchased from Charles River (Wilmington, MA). 
RAW264.7 cells were purchased from ATCC (Manassas, VA, authenticated by ATCC using cell 
morphology, karyotype analysis, and cytochrome C oxidase analysis, and cultured for less than 
six months). Pan02 cells were obtained from the DCTD Tumor Repository (NCI) (Frederick, 
MD, authenticated by NCI using cell morphology, and cultured for less than six months). Fetal 
bovine serum (FBS), neocuproine, ascorbic acid, ammonium acetate, concentrated hydrochloric 
acid (HCl) were purchased from Sigma-Aldrich (St. Louis, MO).  RPMI, Geneticin (G418), 
hygromycin and penicillin-streptomycin were purchased from Invitrogen (Carlsbad, CA). 
Thiazolyl blue and sodium dodecyl sulfate were purchased from Fisher Scientific (Pittsburgh, 
PA). Iron/iron oxide (Fe/Fe3O4) nanoparticles were obtained from NanoScale Corporation 
(Manhattan, KS). Ferrozine was purchased from Hach (Loveland, CO). 
 Cell Culture of RAW264.7monocyte/macrophages and PanO2 pancreatic 
adenocarcinoma cells 
RAW264.7 cells were cultured in RPMI medium containing 10% FBS, with 100 g/mL 
G418 and 100 g/ml hygromycin in a 37°C humidified incubator with 5% CO2. Pan02 cells were 
cultured in RPMI with 10% FBS and 1X penicillin-streptomycin in a 37 °C humidified incubator 
with 5% CO2. 
 Synthesis of Nanoparticles 
 Complete synthesis and characterization of Iron/iron oxide (Fe/Fe3O4) stealth coated bi 
magnetic nanoparticles (MNPs) used in this study were explained in detail in Matt et al., 2012 
[147] 
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 Loading Mo/Ma with Nanoparticles and Determination of Iron Loading 
Concentration 
To determine the optimal concentration for nanoparticle loading, Mo/Ma were plated in 
24 well plates and allowed to come to 70% confluency. Medium was removed from the cells and 
fresh medium was added containing from 0 to 200g/mL iron from the nanoparticles. Sixteen 
hours later the medium was removed, the cells were washed with PBS, and fresh medium was 
added. Loading confirmation and concentration were obtained by lifting the cells and running a 
ferrozine assay for iron content. The percent of cells loaded was measured using flow cytometry. 
Cytotoxicity was measured using the MTT assay.   
For injections, Mo/Ma were cultured to 70% confluency in T75 flasks. Sixteen hours 
before using the cells, cells for groups 3 and 5 (see below) were given nanoparticles consisting of 
373g (37.3g/mL) of iron added to the media in 100 L of PBS and mixed well. At the same 
time, cells for groups 1, 2, and 4 were given 100 L of PBS. The next morning, the medium was 
removed, the cells were washed with PBS, and fresh medium was added. The cells were lifted by 
scraping and counted in a hemocytometer. The correct cell density was attained by spinning the 
cells in 15 mL conical tubes at 1000 RPM for 5 minutes and resuspending in the correct volume 
of PBS to give 2,000,000 cells in 100 L. 
 Loading Strategy of MNPs and Determination of Iron Amounts 
To determine the iron content of the nanoparticle solutions and the nanoparticle loaded 
cells, a ferrozine assay for iron was carried out. Ferrozine reagent was prepared by dissolving 
9.7g ammonium acetate and 8.8g of ascorbic acid in 10 mL of water. 80mg of ferrozine and 
80mg of neocuprine were added to the solution and water was added to bring the total volume to 
25 mL. The sample to be measured (either cell suspension or nanoparticle solution) was diluted 
to appropriate concentrations in deionized water. For cell suspension samples, the cells were 
counted on a hemocytometer using trypan blue before dilution. 2 mL of the diluted sample was 
then placed in a test tube and 0.5 mL of 1.2 M HCl and 0.2 mL of 2M ascorbic acid was added. 
The sample was then vortexed and incubated at 70°C for 1 hour. 0.2 mL of the ferrozine reagent 
was then added to the test tube and the sample was incubated at room temperature for 30 min. A 
standard curve was also prepared with 0, 0.1, 0.2, 0.5, 1, 2, and 5 g/mL iron and treated in the 
same way. After the second incubation, the absorbance at 562 nm of the standard curve and the 
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samples was measured. The absorbance at 562nm versus iron concentration was plotted for the 
standard curve and the sample concentration was determined. 
 Determination of MNPs loaded cells by using Flowcytometry 
To find the percent of MNP loaded Mo/Ma, cells were treated with nanoparticles 
consisting of 5,10,15,20,or 25 µg/mL Fe. The cells were incubated overnight and were washed 
twice with 1x PBS and analyzed by flow cytometry (Guava Easycyte Plus System, Millipore 
Corporation, MA). Side scatter was measured and was used as a marker for nanoparticles; cells 
with increased side scatter compared to control cells were counted as MNP loaded cells. 
Experiment was conducted in triplicate and 10,000 cells were analyzed for each replicate. Data 
were analyzed by using Cytosoft software (Guava Easycyte Plus System, Millipore Corporation, 
MA). 
 MTT Assay 
Thiazolyl blue was dissolved in PBS at 5 mg/mL to give the reagent solution. MTT 
buffer solution was prepared as 10% (w/v) sodium dodecylsulfate and 0.1 M HCl in water. To 
assay cell viability the reagent solution was added 1:10 to the cell medium and the cells were 
placed back into the incubator. After four hours, the MTT buffer solution was added 1:1 to the 
medium and the plates were placed back into the incubator overnight. After incubating, the 
absorbance at 550 nm and 690 nm was recorded.  The quantity ABS550 – ABS690 was calculated 
and the control value was scaled to 100% cell viability. 
 Evaluation Tumor Homing ability of Raw 264.7 cells towards PanO2 tumors  
To test the homing ability of Mo/Ma cells on Pan02 tumors, 7x10
5
 Pan02 cells were 
injected i.p. to two mice on day 0. On day 4, 1x10
6
 PKH26 red fluorescent dye labeled Mo/Ma 
cells were injected i.p. (manufacturer’s instructions were followed for PKH26 labeling). Mice 
were euthanized on day 7 and 10, and tissues (mesentery/tumor, kidney, liver, spleen, lung) 
collected and fixed in buffered neutral formalin. Twenty-four hours after fixation, tissues were 
incubated in sucrose gradient and snap frozen. 5-8 micron sections were made and stained with 
Hoechst for nuclear counter-staining; serial sections were stained with hematoxylin and eosin 
(H&E). 
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To verify that Mo/Ma cells were in Pan02 tumors, 7x10
5
 Pan02-fluc cells (which express 
firefly luciferase intracellularly) were injected i.p. to five mice on day 0. On day 13, 1x10
6
 
Hoescht labeled Mo/Ma cells were loaded with MNP and were injected i.p. Mice were 
euthanized on day 17 and tissues were snap frozen. 5-8 micron sections were made and stained 
with rabbit -firefly luciferase antibody and DyLite649 conjugated sheep -rabbit Igg antibody.   
 Magnetic Heating Apparatus to generate AMF 
The AMF was generated by a converted 10 kW commercial inductive heater. In these 
experiments, only 1.5 kW power was used to produce 145 kHz sinusoidal alternating magnetic 
field in a copper coil. The magnetic field intensity has been calculated to be approximately 0.05 
Tesla. The 4 turn 1” diameter coil is coated with silver and water cooled to eliminate residual 
heating effects from the resistive loss. The diameter of the coil was chosen to facilitate the 
complete inclusion of mice studies in the experiments including a perforated plastic tube.  
 Intratumoral Nanoparticle Heat Generation 
Six C57BL/6 mice (11 weeks old) were injected with 700,000 Pan02 cells in 100 L PBS 
subcutaneously. To create a model for intratumoral heat generation by the loaded Mo/Ma, 21 
days later, when tumors were palpable, 1,000,000 Mo/Ma loaded with nanoparticles were 
injected in 10 L PBS intratumorally at multiple places to three of the mice. The other three 
mice received 1,000,000 unloaded Mo/Ma in 10 L PBS intratumorally. After injections, the 
mice were euthanized and the tumors were removed. The temperature of the tumors was 
recorded using an infrared camera. The tumors were then exposed to AMF for 15 min and the 
temperature of the tumors was again measured using the infrared camera. The difference in 
temperature before and after AMF was calculated and the loaded and unloaded monocyte groups 
were compared. 
 In Vivo Experiment 
C57BL/6 mice (11 weeks old) were injected with 700,000 Pan02 cells in 100 L PBS 
intraperitoneally (i.p.) on day 0 to generate a murine model of disseminated pancreatic cancer. 
These mice were then randomly divided into five groups as follows: (1) tumor control; (2) 
Mo/Ma control; (3) nanoparticle control; (4) AMF control; and (5) AMF treatment. 
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On day 5, 2,000,000 Mo/Ma loaded with the nanoparticles were injected in 100 L PBS 
i.p. to groups 3 (nanoparticle control) and 5 (AMF treatment). Groups 2 (Mo/Ma control) and 4 
(AMF control) also received 2,000,000 Mo/Ma which were not loaded. Group 1 (tumor control) 
received 100 L PBS i.p. This procedure was repeated on days 9 and 13. 
On day 8, mice from groups 4 (AMF control) and 5 (AMF treatment) were anesthetized 
with isofluorane and exposed to an AMF for 20 minutes. This procedure was repeated on days 
12 and 16.   
After three rounds of treatments, the mice were closely observed and allowed to continue 
until they displayed signs of clinical symptoms of cancer, at which point they were euthanized 
using CO2, and the tumors were collected and weighed (Figure 3-5A). 
 Duration to Clinical Symptoms 
The measured outcome for this study was mouse survival. To minimize potential pain 
and distress of the mice, however, a system was developed that allowed the euthanasia of the 
mice shortly before they died. The mice were scored numerically 1 - 5 based on the body 
condition of the mice (primarily the spine and dorsal pelvic bone prominence) with a score of 3 
indicative of a healthy mouse. This initial score was then modified by the presence of extreme 
lethargy, dehydration, ataxia, head tilt, severe hunching, limb dragging, severe raised hair, 
Harderian gland secretions, ascites, labored breathing, or bloody tail. If pronounced, these 
symptoms led to a subtraction of 1 point from the BCS score while mild cases led to the addition 
of a ‘minus symbol‘ to the score (e.g. 3-). The mice were scored by this system every 12 hours 
and any mouse that scored a 2 or less was euthanized and the day/time was recorded. The 
euthanasia day/time data were then treated like survival data and modeled using Kaplan-Meier 
statistics to determine the statistical significance of the data. 
 Results 
 Toxicity and Loading of Nanoparticles  
The nanoparticles did not show any toxicity at concentrations less than 100 g/mL Fe, 
although some slight toxicity was shown at 100 and 200 g/mL Fe (Figure 3-1A). Mo/Ma took 
up the nanoparticles in a manner proportional to the iron concentration (Figure 3-1B). The 
percentage of cells containing nanoparticles (defined as cells that exhibit increased side scatter 
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after loading) also increased in a manner proportional to the iron concentration (Figure 3-1C). 
Based on these results, to prevent undesired toxicity while maximizing the amount of iron 
loaded, nanoparticles were loaded at 37.5 g/mL Fe for the in vivo experiment. To determine the 
exact amount of iron loaded in the cells for the in vivo experiment, when Mo/Ma were lifted for 
the in vivo experiment, excess cells were collected and iron content was measured using the 
ferrozine assay. The iron content of Mo/Ma injected was 2.12 +/- 0.37 pg Fe/cell or 4.25 +/- 0.74 
g Fe/2,000,000 cells. 
 Tumor Homing Studies 
To determine if monocyte-like cells would home to Pan02 tumors, two mice bearing i.p. 
Pan02 tumors were injected i.p. with PKH26 labeled Mo/Ma. Three days after injection, the first 
mouse was euthanized. Tissue imaging showed that the monocyte-like cells effectively homed to 
the tumor, but did not infiltrate other organs, including the pancreas, spleen, liver, and kidney. At 
six days, the second mouse was sacrificed and tissue imaging showed again that the monocyte-
like cells penetrated tumor tissue but not healthy tissue (Figure 3-2).  
To further verify that the monocyte-like cells were, in fact, in tumor tissue, five mice 
bearing i.p. Pan02 tumors expressing firefly luciferase were injected i.p. with Hoescht labeled 
Mo/Ma which were loaded with MNP. Four days after injection, the mice were euthanized.  
Antibody staining for firefly luciferase demonstrated that the Mo/Ma were in tumor tissue 
(Figure 3-3). H&E staining of serial sections demonstrate that the tissue that the Mo/a home to is 
highly disorganized, indicative of tumor tissue (Figure 3-3B). 
 Nanoparticle Heating of Tumors  
To verify that the cell-delivered nanoparticles could cause significant heating of the 
tumor, a subcutaneous Pan02 model was generated. (The subcutaneous model was used to give 
more accessible tumors for measurement purposes). The temperature change caused by AMF 
induced hyperthermia using the nanoparticle loaded Mo/Ma was 4.0+/-0.7°C after 15 min of 
AMF exposure, or moderate hyperthermia. As a comparison, the temperature change using the 
unloaded Mo/Ma was 1.0+/-0.5°C (Figure 3-4, p value = 0.0056).   
40 
 
 Mouse Survival 
To determine the effectiveness of the treatment, Pan02 tumors were given i.p. to 
C57BL/6 mice and the mice were treated as described in the methods section. The euthanasia 
data were collected and modeled using Kaplan-Meier survival statistics. The data are reported as 
days subsequent to tumor injection (day 0) (Figure 3-5B). The Kaplan-Meier test showed that the 
survival curves were significantly different (p<0.005). All of the mice from the tumor control 
group were euthanized due to clinical symptoms (here after referred to as ‘succumbed’) by day 
23. Similarly all of the Mo/Ma control mice succumbed by day 25, all of the nanoparticle control 
mice succumbed by day 26 and all of the AMF control mice succumbed by day 25. Modeling 
with Kaplan-Meier statistics showed no significant difference between any of these groups. The 
AMF treatment mice survived substantially longer, with mice lasting until 33.5 days. The 
survival of the AMF treatment group was shown to be significant against all control groups 
(p<0.005 for all comparisons). The average increase in survival versus tumor control for the 
nanoparticle treatment group was 7 days, a 31% increase in life expectancy post tumor insertion.  
 Discussion 
Here we have shown that tumor-homing cells can specifically deliver MNP for AMF 
therapy, and this treatment can significantly prolong the lives of mice bearing deep and 
disseminated intraperitoneal pancreatic tumors. MNP were loaded into Mo/Ma cells which we 
demonstrated to be tumor homing cells. The Mo/Ma cells were injected i.p. into tumor bearing 
mice and trafficked specifically to the tumor. Three days later, the mice were exposed to AMF, 
which caused the nanoparticles to generate heat, leading to localized hyperthermia. 
We found that the mouse monocytes homed effectively to the pancreatic tumors after i.p. 
administration. This is not surprising because monocytes and/or macrophages are often found as 
tumor-associated cells. Rat monocytes were shown to efficiently invade rat glioma spheroids in 
vitro, and peritoneal macrophages specifically migrated to rat gliomas after intravenous or 
intracarotid administration [140, 141]. Interestingly, in this case, the mouse monocytes 
physically migrated only to the tumors within the peritoneal cavity, while normal tissues did not 
contain monocytes. 
Classically, hyperthermia kills tumor tissue by heating proteins and other 
macromolecules to the point of denaturing faster than the cell can renature them. Since the 
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system demonstrated here was substantially effective with only 4 g of iron injected into the 
mouse per treatment cycle, other mechanisms of action may be present. The nanoparticle control 
group demonstrates that the nanoparticles themselves do not have any treatment value; similarly, 
the AMF control group demonstrates that AMF treatment does not have any stand-alone value. 
The Mo/Ma control group demonstrates that the Mo/Ma neither increase nor decrease tumor 
growth. Thus, AMF activation of the MNP is primarily responsible for the effect. Low grade 
hyperthermia has been shown to recruit various immune cells including dendritic cells, natural 
killer (NK) cells, neutrophils, and cytotoxic T cells [148-156]. Although future studies need to be 
done, this or another similar mechanism may have greatly increased the effectiveness of the 
treatment and could explain why such a low dose of MNP can effect such a large survival 
advantage.  We are currently investigating potential mechanisms involved in mediating the 
survival extension, and those results will be described in a subsequent report. 
 Conclusion 
In this report, we have described the development of a localized hyperthermia treatment 
using tumor-tropic cells, monocyte/macrophage-like cells, to deliver MNP for AMF activation . 
The system we describe here holds potential for further development as a specific delivery 
method for MNP-generated localized hyperthermia for targeted therapy of pancreatic and other 
types of cancer. 
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Figure 3-1 MNPs toxicity and loading studies on RAW 264.7 Mo/Ma cells 
Mo/Ma were cultured overnight in increasing concentrations of nanoparticles. The next morning 
cells were washed and assayed. A. Toxicity of Nanoparticles: Cells were assayed for viability 
using MTT.  B. Loading of Nanoparticles: Cells were assayed for iron content using the 
ferrozine assay.  C. Percent of Cells Loaded: Cells were assayed for increased side scatter using 
flow cytometry.  Error bars are standard deviation. 
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Figure 3-2 RAW 264.7 Mo/Ma homing studies on PanO2 pancreatic tumors 
PKH26 labeled monocytes were injected i.p. into mice bearing i.p. Pan02 tumors.  A-F. Mice 
were euthanized three days after monocyte injection and organs were harvested and imaged for 
PKH26 (monocytes).  Representative images are shown. A. Tumor 10x; B. Tumor 40x; C. 
Pancreas; D. Kidney; E. Liver; F. Lung.  G-L.  Mice were euthanized six days after monocyte 
injection and organs were harvested and imaged for PKH26 (monocytes).   Representative 
images are shown. G. Tumor (note healthy pancreas at the top left); H. Tumor; I. Pancreas; J. 
Kidney; K. Liver; L. Lung.   Blue is DAPI (nuclear counterstain), Red is PKH26 (monocytes).  
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Figure 3-3 Mo/Ma infiltration into Pan02 tumors. 
A, B. Mo/Ma loaded with PKH26 were injected into mice bearing i.p. Pan02 tumors.  Six days 
later mice were euthanized and tumors were harvested.  A. Dapi counterstained section shows 
Mo/Ma labeled with PKH26 in tumor.  Blue = Dapi, Red = PKH26 (Mo/Ma).  B. H&E staining 
of serial sections shows irregular morphology demonstrating that the targeted area is a tumor. 
Scale bars = 100 m.  C. Mo/Ma loaded with Dapi were injected into mice bearing Pan02(fluc) 
tumors.  Five days later mice were euthanized and tumors were harvested.  Sections were stained 
with rabbit anti-firefly luciferase and DyLite649-goat anti rabbit.  Immunohistochemistry 
verifies that the Mo/Ma infiltrate pancreatic tumors.  Blue = Dapi (Mo/Ma), Red = DyLite 649 
(Pan02 cells).  Scale bar = 100 m. 
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Figure 3-4 Heat generation by nanoparticle loaded Mo/Ma 
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Figure 3-5 Survival study after Mo/Ma (MNP) mediated AMF treatments 
A. In vivo experiment design, B. Duration to Clinical Symptoms (‘Survival’).  Mice were treated 
and monitored as described.  Mice were euthanized when they displayed clinical signs of cancer 
and the day/time was recorded (n=5 or 6 for each group). p<0.005 for AMF treatment versus all 
other groups. 
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 Abstract 
Engineered tumor homing cell mediated targeted delivery of therapeutic proteins has 
been shown to be a potential cancer treatment in pre-clinical studies. This treatment approach 
depends on homing ability and distribution of engineered cells in tumor microenvironment. By 
designing therapeutic chimeric proteins that have tumor microenvironment specific activity, 
increased tumor targeting could be achieved. This report demonstrates design and in vitro testing 
of a chimeric therapeutic protein that has properties such as apoptosis inducing (Caspase3 
V266ED3), prostate cancer cell (CaP) specificity (CaP1 targeting peptide), tumor protease 
specificity (Urokinase and calpain cleavable)- rCasp3V266ED3. By engineering tumor homing 
cells expressing this protein on their membrane (cell surface engineering) different levels of 
treatment specificity that depends on complex characteristics of cancer cells/ tumor 
microenvironment may be attained. In this report, the hypothesized membrane anchored 
chimeric protein (rCasp3V266ED3, rMcherry red) plasmids were constructed, membrane 
anchoring and activity of designed proteins were confirmed in RAW264.7 Mo/Ma and HEK293 
cells in vitro and potential problems that are associated in testing this system were identified. 
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 Introduction 
Prostate cancer is the second leading cancer causing death of men in the USA [157]. 
Available chemotherapeutics for late stage metastatic prostate cancer only have modest 
improvements in survival of patients [158, 159]. Cell based therapeutics for cancer treatment 
becoming a viable treatment approach, because of the targeting ability that can be achieved 
through cells [8]. Many different cells are known to have migratory properties towards tumors 
through complex tumor specific cytokines sensing and response systems [5, 9, 12]. By 
engineering these tumor trophic cells to secrete anti-cancer therapeutics, different research 
groups have shown reliable pre-clinical results supporting the cell based therapeutic approach 
[22-25, 27, 47, 111, 114, 121].  Specificity of an anti-cancer protein secreting, cell mediated 
therapeutic approach depends on the homing ability of the cells towards tumors and distribution 
of cells and secreted anti-tumor protein in the tumor environment [8]. Rapidly developing 
engineering approaches to manipulate cells are helping in design more sophisticated cell based 
therapeutics [8, 160]. By controlling the expression of anti-tumor therapeutics in delivery cells 
with cancer microenvironment specific promoters, more targeting can be achieved [13] . At the 
same time by designing chimeric therapeutic proteins that have tumor microenvironment 
dependent activity, increased tumor targeting can potentially be attained. 
  Caspase3 V266ED3 is a mutant Caspase 3 protein that has apoptosis inducing properties 
and could be used as therapeutic protein [161, 162]. In the present study, chimeric therapeutic 
protein (rCasp3V266ED3) containing properties such as apoptosis inducing (Caspase3 
V266ED3), prostate cancer cell (CaP) specificity (CaP1 targeting peptide), tumor proteases 
specificity (Urokinase and calpain clevable) was designed [163, 164]. By engineering tumor 
homing cells expressing this protein on their membrane (cell surface engineering) different levels 
of treatment specificity that dependent on complex characteristics of cancer cells/ tumor 
microenvironment can potentially be attained.  The designed therapeutic protein sequence with 
assigned specificities is shown in Figure 4-1. Targeting levels that may be possible with this 
hypothesized system are as follows; 1. Migration of engineered tumor homing cells towards 
tumors, 2. Urokinase/Urokinase plasminogen activator (uPA) mediated cleavage and release of 
chimeric protein that is present on tumor homing cells into tumor microenvironment, 3. CaP1 
prostate cancer cell specific targeting peptide mediated uptake of chimeric protein into prostate 
cancer cells and 4. Calpain mediated release of  Caspase3 V266ED3 protein inside prostate 
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cancer cells and apoptosis. In this report, two hypothesized membrane anchored chimeric protein 
(rCasp3V266ED3, rMcherry red) plasmids were constructed,  membrane anchoring and the 
activity of designed proteins were analyzed in RAW264.7 Mo/Ma and HEK293 cells. Further, 
Urokinase (tumor specific protease) mediated cleavage and release of chimeric protein was 
tested. 
 Materials and Methods 
 Reagents and cells 
Raw264.7 and HEK293 cells were purchased from ATCC (Manassas, VA). Dulbecco's 
Modified Eagle's Medium (DMEM), Roswell Park Memorial Institute medium 1640 medium 
(RPMI 1640), penicillin (10,000 units/mL)/streptomycin (10,000 μg/mL) were purchased from 
Life Technologies (Grand Island, NY). Fetal bovine serum (FBS), Glutamax, Sodium pyruvate, 
Trypsin- ethylenediaminetetraacetic acid (EDTA), Phospholipase C- Phosphoinositidyl specific 
enzyme (PI-PLC), were purchased from Sigma-Aldrich (St. Louis, MO). Turbofect transfection 
reagent was purchased from Thermo scientific. Rediplate 96 Enz check caspase-3 assay kit, 
pVac1-MCS plasmid, Alexa fluor 568 goat anti-rabbit secondary antibody and Alexa fluor 488 
goat anti-mouse secondary antibody were purchased from Invitrogen (Eugene,OR). Rabbit 
monoclonal antibody to Caspase-3 was purchased from Abcam. Rabbit anti mcherry Ab was 
purchased from Biovision. HRP conjugated goat anti-rabbit was purchased from Millipore. Beta 
actin antibody was purchased from Fritzgerald (Acton,MA). Recombinant human Urokinase 
plasminogen activator (rhUPA) was purchased from R&D systems (Minneapolis, MN). Native 
membrane protein extraction kit was purchased from Calbiochem. Fluorescence measurements 
for DEVD assay and mcherry red were conducted by using an IVIS lumina-II imaging system 
(Perkin-Elmer). 
 Cell culture 
RAW264.7 cells were cultured in phenol red free RPMI medium containing 10% FBS, 
with 1% penicillin/ streptomycin in a 37°C humidified incubator with 5% CO2. HEK293 cells 
were cultured in phenol red free DMEM medium containing 10% FBS, 1x sodium pyruvate, 1x 
Glutamax with 1% penicillin/ streptomycin in a 37°C humidified incubator with 5% CO2. PC3 
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prostate adeno carcinoma cells were cultured in F12-K medium containing 10%FBS with 1% 
penicillin/ streptomycin in a 37°C humidified incubator with 5% CO2. 
 Recombinant gene design (in silico) and designed plasmids preparation  
Recombinant Caspase-3V266ED3 (rCasp3V266ED3) gene was designed in CLC work 
bench software. The constitutively active human Caspase 3 V266ED3 gene sequence was used 
as the main back bone in gene design [161, 162]. Literature referenced urokinase plasminogen 
activator (uPA) cleavage site (SGRSA) [165] and calpain (PLFAER) [166] cleavage site amino 
acid sequences were reverse translated into DNA sequences in silico. Calpain cleavage site DNA 
sequence was attached to N-terminal side of Caspase 3 V266ED3 sequence and uPA cleavage 
site DNA sequence was attached to C-terminal side of Caspase 3 V266ED3 sequence. Prostate 
cancer specific targeting peptide-1 (Cap1) (SGESVQVKSTKIG) DNA sequence was attached 
before calpain cleavage site DNA sequence.Cap1 prostate cancer specific peptide was identified 
in Dr. Eskew lab in KUMC by using peptide phage display against human prostate cancer cell 
line PC3 (not yet published). Bam H1, EcoR1 restriction sites were attached at 5’ and 3’ 
respectively for sub-cloning into pVac1- MCS vector. Complete rCasp3V266ED3 gene sequence 
with its estimated protein sequence was shown in Figure 4-1. Recombinant mcherry red 
(rMcherry red) gene was designed in the same way as explained above, but instead of Caspase 3 
V266ED3 gene sequence Pubmed referenced mcherry red sequence was used. Designed 
rCasp3V266ED3 and rMcherry red sequences containing PUC19 vectors were purchased from 
Genescript and sub cloned into pVac1-MCS vector by restriction digestion and ligation. 
 Constructed pVac1- rCasp3V266ED3 (Figure 4-2A) and pVac1-rMcherry red plasmids were 
confirmed by using EcoR1 and BamH1 restriction double digestion and digested products size 
verification (Figure 4-2B). IL-2 signal sequence and the glycosylphosphatidyl inositol (GPI) 
anchoring domain of human PLAP of pVac1-MCS plasmid helps in expressed rCasp3V266ED3 
protein secretion and cell membrane anchoring. Constructed pVac1- rCasp3V266ED3  plasmid 
map and predicted rCasp3V266ED3 protein tertiary structure was shown in Figure 4-2A and C. 
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 rCasp3V266ED3 protein expression studies on Raw 264.7 Mo/Ma cells 
 Testing rCasp3V266ED3 protein expression mediated toxicity 
To check designed rCasp3V266ED3 expression mediated toxicity, Raw 264.7 Mo/Ma 
cells were transfected with pVac1- rCasp3V266ED3 plasmid by using Turbofect transfection 
reagent following manufacturer’s protocol. 24 and 48 hours after transfecion, cell viability was 
analyzed by using trypan blue counting. Un-transfected (No transfection), Turbofect added and 
pVac1-rMcherry red transfected cells were used as controls for relative comparison of live cell 
numbers.   
 Membrane anchored rCasp3V266ED3 protein expression confirmation  
To confirm designed rCasp3V266ED3expression and membrane anchoring Raw 264.7 
Mo/Ma cells were transfected with pVac1-rCasp3V266ED3 plasmid. 24-48 hrs after transfection 
cells were incubated with 1:50 Rabbit monoclonal antibody against human Caspase3 (Abcam) 
(Assuming Caspase3 antibody can attach to rCasp3V266ED3 protein) for 1hour after 
4%paraformaldehyde fixation and blocking. After primary antibody incubation, transfected cells 
were incubated with Alexa fluor 568 goat anti-rabbit secondary antibody (Molecular probes-
1μg/mL) for 1hour. Nuclei were counterstained with 2µg/mL Hoechst 33342. Un-transfeted and 
secondary antibody treated cells were used as controls for relative comparison. The antibody 
used here has no cross reactivity with mouse caspase3 and cells were not pemeabilized before 
primary antibody incubation (membrane immunostaining). 
 Direct co-culture of rCasp3V266ED3 expressing Mo/Ma cells with PC3 cells 
PC3 cells were known to secrete uPA into their culture medium [167]. Based on the 
proposed hypothesis direct co-culture of PC3 cells with rCasp3V266ED3 expressing Mo/Ma 
cells should lead to release of rCasp3V266ED3 protein from Mo/Ma cells and should show 
toxicity on PC3 cells. To test this, Raw 264.7 Mo/Ma cells were transfected with pVac1-
rCasp3V266ED3 plasmid and co-cultured with PC3 cells in 1:1 ratio cell number. PC3 cells co-
cultured with un-transfected Mo/Ma and pVac1-rMcherryred transfected Mo/Ma cells were used 
as controls for cell viability comparison. Cell viability was analyzed by using MTT assay after 
48 and 72 hrs of co-culture 
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 rhUPA treatment on rCasp3V266ED3 protein expressing Raw 264.7 Mo/Ma cells and DEVD 
assay 
Based on design of the protein, urokinase treatement should cleave the membrane 
attached rCasp3V266ED3 protein and release it from the cells. To check this hypothesis Raw 
264.7 Mo/Ma cells were transfected with pVac1-rCasp3V266ED3 plasmid. 24-48 hrs after 
transfection cells were washed with 1xPBS and assay buffer containing 10mM Trisc-Cl 
pH7.4/0.25M sucrose/10mM glucose for three times. Around 200,000 cells were suspended in 
50µL of assay buffer containing 1.5units of recombinant human urokinase plasminogen activator 
(rhUPA) and incubated for 1.5hrs at 37˚C in incubator. After incubation, cells were spun at 
12000g and supernatant were collected. Collected supernatants DEVD activity was measured by 
using Rediplate 96 Enz check caspase-3 assay kit by following manufacturer’s protocol. pVac1-
rCasp3V266ED3 transfected but rhUPA untreated and Un-transfected rhUPA treated or 
untreated Mo/Ma cells were used as controls for this experiment.  
 Total cell protein rCasp3V266ED3 protein activity confirmation 
Caspase-3 V266ED3 protein is known to have DEVD peptide cleavage ability [161]. To 
check DEVD peptide cleavage activity Raw 264.7 Mo/Mo cells were transfected with pVac1-
rCasp3V266ED3 plasmid. 24-48 hrs after transfection and total cellular proteins from 6 x10
6
 
transfected cells were separated and DEVD activity was measured by using Rediplate 96 Enz 
check caspase-3 assay kit following manufacturer’s protocol. Ac-DEVD-CHO was used as a 
blocker control for the assay. Un-transfected cell protein test of DEVD activity was used as 
controls for relative comparison. At the same time to check the kit working capacity, doxorubicin 
treated PC3 cells proteins were used as positive control. 
 rCasp3V266ED3 protein expression studies on HEK293 cells 
 Testing rCasp3V266ED3 protein expression mediated toxicity 
To check designed rCasp3V266ED3 expression mediated toxicity, HEK293 cells were 
transfected with pVac1- rCasp3V266ED3 plasmid by using Turbofect transfection reagent 
following manufacturer’s protocol. 24 -48 hours after transfecion, cell viability was analyzed by 
using trypan blue counting. Un-transfected (control), pVac1-MCS (empty vector) and pVac1-
rMcherry red transfected cells were used as controls for relative comparison of live cell numbers.  
54 
 
 rCasp3V266ED3 protein activity confirmation 
To check DEVD peptide cleavage activity, HEK293 cells were transfected with pVac1-
rCasp3V266ED3 plasmid. 24-48 hrs after transfection total cellular proteins from 2 x10
6
 
transfected cells were separated and protein concentration estimated. DEVD activity was 
measured by using Rediplate 96 Enz check caspase-3 assay kit following manufacturer’s 
protocol, For each sample ~130µg of protein was used. Ac-DEVD-CHO was used as a blocker 
control for the assay and pVac1-MCS (empty vector) transfected HEK293 cell proteins DEVD 
activity was used as control for relative comparison. Protein samples were immunoblotted with 
Caspase 3 antibody after DEVD assay. The same blots were re-blotted with β-actin antibody for 
relative protein amount comparison. 
 Membrane anchored rCasp3V266ED3 protein expression and activity confirmation 
To confirm designed rCasp3V266ED3 membrane expression and activity, HEK293 cells 
were transfected with pVac1-rCasp3V266ED3 plasmid. 24 -48 hours after transfection 
membrane proteins were separated by using Calbiochem proteo extract native membrane protein 
extraction kit following manufacturer’s protocol. Separated proteins were concentrated by using 
Millipore amicon filters and protein concentration was estimated. ~50µg membrane protein 
DEVD activity was measured by using Rediplate 96 Enz check caspase-3 assay following 
manufacturer’s protocol. Un-transfected (control), pVac1-MCS (empty vector) transfected 
HEK293 cells membrane proteins were used as controls for relative comparison. Protein samples 
were immunoblotted with Caspase 3 antibody after DEVD assay. 
 rhUPA or PLC treatment on rMcherry red  protein expressing HEK293 cells  
Based on design of the rMcherry red protein, urokinase treatement or Phospholipase 
(PLC) treatment should cleave the membrane attached rMcherry red protein and release it from 
the cells. To check this hypothesis HEK293 cells were transfected with pVac1-rMcherry red 
plasmid. 24-48 hrs after transfection cells were washed with 1xPBS and assay buffer (10mM 
Trisc-cl pH7.4/0.25M sucrose/10mM glucose) for three times. 200,000 cells were resuspended in 
50µL of above mentioned buffer and 1unit of rhUPA or 1 unit of PLC was added to cells and 
incubated for 1.5hrs at 37˚C in incubator. After incubation, cells were spun at 12000g and 
supernatant were collected. Collected supernatant fluorescence was measured. pVac1-rMcherry 
red transfected rhUPA untreated and Un-transfected rhUPA treated/untreated HEK293 cells were 
55 
 
used as controls for relative supernatant fluorescence comparison. Same above experiment was 
repeated with 400,000 and 800,000 transfected cells. 
 rCasp3V266ED3 protein expression studies on PC3 cells 
PC3 cells were known to secrete uPA into their culture medium[167]. Based on the 
proposed hypothesis, membrane expressed rCasp3V266ED3 should be cleaved  from the 
membrane and should show toxicity on PC3 cells after pVac1-Casp3V266ED3 transfection. To 
test this concept, PC3 prostate carcinoma cells were transfected with pVac1-rCasp3V266ED3 
and 24-48hrs after transfection cell viability was analyzed by using trypan blue counting.  
pVac1-rMcherryred transfected PC3 cells were used as control for comparative analysis. 
 Statistical analysis 
Statistical analyses were performed using WinSTAT (A-Prompt Corporation, Lehigh 
Valley, PA). Experiments that were designed based on one factor were analyzed by using one 
way ANOVA with LSD post hoc analysis. Experiments that were designed based on two factors 
were analyzed by two way ANOVA (with interaction effect) and LSD post hoc analysis. All the 
bars in graphs were represented by mean ± standard error. p-Value <0.05 was considered as 
significant for all the analyses. 
 Results &Discussion 
 rCasp3V266ED3 protein expression studies on Raw 264.7 Mo/Ma cells 
 Testing rCasp3V266ED3 protein expression mediated toxicity 
To determine whether rCasp3V266ED3 protein expression has any toxic effect, pVac1- 
rCasp3V266ED3 transfected Mo/Ma cell viability was analyzed by using trypan blue counting 
after 24 and 48 hrs of transfection. There is no significant difference between pVac1-rMcherry 
red transfected Mo/Ma and pVac1-rCasp3V266ED3 transfected Mo/Ma live cell percentage 
(Figure 4-3A). Although there was significant difference between un- transfected cells (No 
transfection) and pVac1-rCasp3V266ED3 transfected Mo/Ma live cell percentage, similar toxic 
effect was observed with pVac1-rMcherry red transfected Mo/Ma cells. So, the observed toxic 
effect could be because of plasmid DNA and tubofect polymer complex or plasmid DNA itself. 
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 rCasp3V266ED3 protein membrane expression in pVac1- rCasp3V266ED3 transfected Mo/Ma 
cells were confirmed with immunocytochemistry (Figure 4-3A(b)). The antibody used here only 
reacts with human caspase 3 but it doesn’t react with mouse caspase 3.As from the picture 
(Figure 4-3A(b)) very few cells were expressing rCasp3V266ED3 protein on their membrane, 
indicating that the transfection efficiency was very low. At the same time rMcherry red 
membrane expression was confirmed in pVac1- rMcherry red transfected Mo/Ma cells (Figure 
4-3A(a)) by using anti mcherry red antibody. Some cells expressing rMcherry red protein (Figure 
4-3A(a)- white arrows) didn’t show positive for mcherry red immunocytochemistry, indicating 
there is difference in membrane trafficking of designed chimeric rMcherry red protein in 
transfected cells. 
 Direct co-culture of rCasp3V266ED3 expressing Mo/Ma cells with PC3 cells 
PC3 cells are known to secrete uPA into their culture medium [167]Based on the 
proposed hypothesis, direct co-culture of PC3 cells with rCasp3V266ED3 expressing Mo/Ma 
cells should lead to release of rCasp3V266ED3 protein from Mo/Ma cells and should show 
toxicity on PC3 cells. To test this hypothesis, pVac1- rCasp3V266ED3 transfected Mo/Ma cells 
were directly co-cultured with PC3 cells (1:1 ratio) and cell viability was analyzed by MTT 
assay after 48hrs and 72hrs of co-culture. As shown in Figure 4-4 there is no significant 
difference between viability of PC3 cells co-cultured with Mo/Ma cells expressing 
rCasp3V266ED3 and PC3 cells co-cultured with Mo/Ma cells expressing rMcherry red protein. 
Same co-culture experiments were repeated with 1:2 ratio of Mo/Ma and PC3 cells and similar 
results were observed. rCasp3V266ED3 mediated toxicity depends on number of Mo/Ma cells 
expressing rCasp3V266ED3 protein on their membrane (transfection efficiency of pVac1- 
rCasp3V266ED3) and amount of uPA released by PC3 cells into culture medium. Although 
Figure 4-4 is opposing the proposed hypothesis, above mentioned reasons could be a potential 
technical problem to test the system. 
 rCasp3V266ED3 protein activity confirmation 
To check whether the designed protein has activity or not pVac1- rCasp3V266ED3 
transfected cell lysates DEVD activity was analyzed. When compared with un-transfected and 
pVac1- rMcherry red transfected Mo/Ma cell lysates, no significant difference in DEVD activity 
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was observed (Figure 4-5B cell proteins-NS). Rediplate 96 Enz check caspase-3 assay kit 
working efficiency was confirmed by using doxorubincin treated PC3 cell lysate proteins ( 
Figure 4-5A) One of the possibilities for observing this result could be the low levels of the 
designed chimeric protein. .Lack of rCasp3V266ED3 protein activity could be because of 
additional sequences attached to N-terminal (Cap-1 and calpain cleavage site sequences) and C-
terminal (uPA cleavage site) of Caspase3V266ED3 protein ( 
Figure 4-1). But, predicted tertiary structure of rCasp3V266ED3 protein ( 
Figure 4-2C) suggested that additional sequences were not interfering with Caspase3V266ED3 
protein backbone.  
 rhUPA treatment on rCasp3V266ED3 protein expressing Raw 264.7 Mo/Ma cells and DEVD 
assay 
Based on the design of chimeric rCasp3V266ED3, uPA treatment should lead to release 
of the protein from the membrane. To analyze uPA mediated release of the membrane attached 
protein, pVac1- rCasp3V266ED3 transfected cells were treated with rhUPA and supernatant 
DEVD activity was measured. Difference in DEVD activity observed between rhUPA untreated 
and treated Mo/Ma (pVac1- rCasp3V266ED3) cells supernatants was not significant (Figure 
4-6). But there was significant difference between Mo/Ma and Mo/Ma (pVac1- 
rCasp3V266ED3) supernatants, possibly because of weak GPI anchoring of the designed protein. 
 The above rCasp3V266ED3 protein expression studies on Raw 264.7 Mo/Ma cells were 
confirming the designed chimeric protein membrane expression. Experiments conducted to 
analyze the rCasp3V266ED3 protein activity and rhUPA mediated cleavage of the membrane 
anchored protein didn’t show any positive results supporting the proposed hypothesis. One of the 
strong possibilities for observing these results could be of low transfection efficiency of Mo/Ma 
cells (Figure 4-3B). HEK293 cells were known to have higher transfection efficiency[168], so to 
check the designed chimeric protein system further experiments were carried out with HEK293 
cells. 
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 rCasp3V266ED3 protein expression studies on HEK293 cells 
 Testing rCasp3V266ED3 protein expression mediated toxicity 
To check whether rCasp3V266ED3 protein expression has any toxic effect, pVac1- 
rCasp3V266ED3 transfected HEK293 cell viability was analyzed by using trypan blue counting 
after 24-48 hrs of transfection. There was no significant difference between pVac1-
rCasp3V266ED3 transfected HEK293 live cell percentage compared with other control groups 
(Figure 4-7). Turbofect transfection procedures were optimized with HEK293 cells to reduce the 
transfection mediated toxic effect observed with Mo/Ma cells (Figure 4-3A).  
 rCasp3V266ED3 protein activity confirmation 
To check designed protein activity, pVac1- rCasp3V266ED3 transfected HEK293 cell 
lysates DEVD activity was analyzed. When compared with empty vector (pVac1-MCS) 
transfected HEK293 cell lysates, p-Value 0.1 significant difference in DEVD activity was 
observed ( Figure 4-8 A cell type-0.1). Interestingly, blocker interaction was different with 
pVac1 rCasp3V266ED3 transfected HEK293 cell lysates compared to empty vector transfected 
cell lysates ( Figure 4-8A interaction-0.05). Above samples were further analyzed with Caspase 
3 western blot to confirm the presence of rCasp3V266ED3 protein in pVac1 rCasp3V266ED3 
transfected HEK293 cell lysates. As shown in Figure 4-8B, no difference in caspase3 band 
thickness was observed between two groups on the blot.  
 Membrane anchored rCasp3V266ED3 protein activity and membrane anchoring 
confirmation 
Although pVac1 rCasp3V266ED3 transfected HEK293 total cell lysates ( Figure 4-8A) 
has increased activity, western blots of the analyzed samples didn’t confirm the presence of 
rCasp3V266ED3 in tested samples. Designed protein is supposed to be anchored to the cell 
membrane through GPI linker. So, transfected cells membrane proteins were isolated and DEVD 
activity was measured. When compared to un-transfected and empty vector transfected HEK293 
cells membrane protein, increased DEVD activity was observed in pVac1- rCasp3V266ED3 
transfected HEK293 cells membrane proteins ( Figure 4-9A). Caspase 3 immunoblot analysis 
further confirmed the presence of rCasp3V266ED3 protein in above samples ( Figure 4-9B) 
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 rhUPA or PI-PLC treatment on rMcherry red  protein expressing HEK293 cells  
rMcherry red protein was designed in same way as rCasp3V266ED3 chimeric protein 
with Cap1 peptide, calpain and uPA cleavage sites. Based on design of the rMcherry red protein, 
uPA treatment should lead to release of rMcherry red protein from the cell membrane. To check 
this hypothesis, pVac1- rMcherry red transfected HEK293 cells were treated with rhUPA 
enzyme and supernatants mcherry red fluorescence was analyzed. When compared with rhUPA 
untreated cell supernatants, no significant difference was observed in mcherry red fluorescence 
intensity ( Figure 4-10A). A similar pattern of results were observed when repeated with 
increasing numbers of pVac1- rMcherry red transfected HEK293 cells ( Figure 4-10B).  
PLAP sa sequence in constructed pVac1- rMcherry red plasmid helps in GPI mediated 
membrane anchoring of the rMcherry red protein [169]. Phosphoinositidyl specific 
Phospholipase-C (PI-PLC) is a known enzyme that can cleave this GPI anchor and should 
release the membrane anchored rMcherry red protein [169]. PI-PLC mediated release of rMherry 
red protein from the cell membrane confirms the assay conditions and GPI anchoring. To test 
this, pVac1- rMcherry red transfected HEK293 cells were treated with PI-PLC and supernatant 
fluorescence was analyzed. When compared with PI-PLC untreated cell supernatants no 
significant difference was observed in mcherry red fluorescence intensity ( Figure 4-10C).  A 
similar pattern of results were observed when repeated with increasing numbers of pVac1- 
rMcherry red transfected HEK293 cells ( Figure 4-10B). These results suggest that assay 
conditions should be modified to test uPA mediated release of membrane attached designed 
chimeric protein. 
 rCasp3V266ED3 protein expression studies on PC3 cells 
PC3 cells were known to secrete uPA into their culture medium. Based on the proposed 
hypothesis membrane expressed rCasp3V266ED3 should be cleaved off from the membrane and 
should show toxicity on PC3 cells after pVac1-Casp3V266ED3 transfection. pVac1-
rCasp3V66ED3 transfected PC3 cells didn’t show any decrease in cell viability when compared 
with rMcherry red transfected cells (Figure 4-11). rCasp3V266ED3 mediated toxicity depends 
on number of PC3 cells expressing rCasp3V266ED3 or amount of  the protein on their 
membrane (transfection efficiency of pVac1- rCasp3V266ED3) and amount of uPA released by 
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PC3 cells into culture medium. With these results, it is not possible to reject the proposed 
chimeric rCasp3V266ED3 system. 
rCasp3V266ED3 protein expression studies on HEK293 cells confirmed the designed 
chimeric protein membrane expression and activity ( Figure 4-9). But rhUPA treatment didn’t 
lead to the release of chimeric protein from the membrane ( Figure 4-10A,B). Experiments 
conducted with PI-PLC ( Figure 4-10C,D) suggesting for the modifications in rhUPA assay 
system. One of the strong possibilities for observing these results could be low expression of 
designed chimeric proteins in analyzed cell systems. When the promoter was changed in the 
designed plasmids (rhEF1 to CMV promoter) increased expression of chimeric rMcherry protein 
was observed in HEK293 cells (Figure 4-12- qualitative observation). Retro or lenti viral 
transduction with engineered cell line establishment could help to achieve high expression of 
chimeric proteins on membrane and could help in testing the design protein system by surpassing 
expression mediated possibilities observed in above results. 
 Conclusion 
In the present study, prostate cancer specific (cancer cell specific), urokinase (uPA) & 
calpain tumor proteases cleavable (tumor microenvironment specific) chimeric 
Caspase3V266ED3 (cell toxic protein/therapeutic protein) – “rCasp3V266ED3” was designed. 
Cell membrane anchored rCasp3V266ED3 transgene containing plasmid was constructed 
(pVac1-rCasp3V266ED3). Designed protein rCasp3V266ED3 membrane anchoring, toxicity and 
activity was confirmed by using RAW 264.7 Mo/Ma and HEK293 cells. uPA protease mediated 
release of membrane anchored chimeric protein was tested. Problems in low expression of 
designed protein and further improvements in testing this chimeric protein system were 
identified.  
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Figure 4-1 Designed rCasp3V266ED3 sequence 
Designed rCasp3V266ED3 gene sequence with predicted open reading frame protein sequence, 
predicted sequence was confirmed by using BLAST. Targeting peptide (Cap1) and proteases 
(uPA and calpain) cleavage sequence sites were mentioned on top of designed DNA sequence.  
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Figure 4-2 Constructed pVac1- rCasp3V266ED3 plasmid map and restriction double 
digestion confirmation 
A. Constructed pVac1- rCasp3V266ED3 plasmid map, B. Restriction double digestion 
confirmation of constructed pVac1-rCasp3V266ED3 and pVac1-rMcherry red plasmids (1-1kb 
ladder, 2 &5 - pVac1 rMcherry red, 3&6- pVac1 rMcherry red +EcoR1-HF, 4&7- pVac1 
rMcherry red +EcoR1-HF +BamH1-HF, 8 &11- pVac1 rCasp3V266ED3, 9&12- pVac1 
rCasp3V266ED3+EcoR1-HF, 10&13- pVac1 rCasp3V266ED3+EcoR1-HF +BamH1-HF, 14-
100bp ladder). Estimated insert sizes for pVac1 rCasp3V266ED3 and pVac1 rMcherry red are 
910bps & 790bps, C. Predicted rCasp3V266ED3 protein tertiary structure indicating attached 
additional sequences are not interfering with Caspase3V266ED3 structure. 
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Figure 4-3 rCasp3V266ED3 expression mediated toxicity testing on RAW 264.7 Mo/Ma 
cells and membrane expression confirmation 
A. rCasp3V266ED3 protein expression mediated toxicity on RAW264.7 Mo/Ma cells. There is 
no significant difference between pVac1-rMcherry red transfected Mo/Ma and pVac1-
rCasp3V266ED3 transfected Mo/Ma live cell percentage, B (a).Immunocytochemistry 
confirmation of  rMcherry red membrane expression (red bordered inlet-mcherry red 
fluorescence, green bordered inlet- mcherry red immuno), (b) rCasp3V266ED3 membrane 
expression confirmation (red bordered inlet-.Capase3 immno). 
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Figure 4-4 MTTcell  viability analysis of PC3 cells co-cultured with rCasp3V266ED3 
expressing RAW 264.7 Mo/Ma cells 
Relative live cells percentage comparison between direct co-cultured PC3 cells with Mo/Ma cells 
after 48,72hrs.  Although 2-factor ANOVA was significant, post hoc analysis didn’t show any 
significance between PC3+Mo/Ma (pVac1-rMcherry red) and PC3+Mo/Ma(pVac1-
rCasp3V266ED3). 
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Figure 4-5 rCasp3V266ED3 expressing Mo/Ma total cell proteins DEVD assay 
A. Rediplate 96 Enz check caspase-3 assay kit working efficiency confirmation, there is 
significant difference in DEVD activity between proteins separated from PC3 cells and proteins 
separated from doxorubincin treated PC3 cells confirming kit working efficiency. B.pVac1-
rCasp3V266ED3 transfected Mo/Ma cells total proteins don’t have significant difference in 
DEVD activity when compared with controls. 
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Figure 4-6 rhUPA treatment on rCasp3V266ED3 expressing Raw 264.7 Mo/Ma cells and 
DEVD assay 
pVac1-rCasp3V266ED3 transfected Mo/Ma cells were treated with rhUPA and supernatant 
DEVD activity was measured and plotted. Although overall rhUPA has significant difference 
(rhUPA-<0.05), there is no statistically significant difference between rhUPA treated and 
untreated Mo/Ma (pVac1-rCasp3V266ED3), same kind of pattern was observed with rhUPA 
treated and untreated Mo/Ma.  
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Figure 4-7 rCasp3V266ED3 expression mediated toxicity testing on HEK293 cells 
There is no significant difference between pVac1-rCasp3V266ED3 transfected HEK293 live cell 
percentage compared with other control groups . Turbofect transfection procedures were 
optimized with HEK293 cells to reduce the transfection mediated toxic effect observed with 
Mo/Ma cells (Figure 4.3A).  
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 Figure 4-8 rCasp3V266ED3 protein activity confirmation 
rCasp3V266ED3 expressing HEK293 total cell proteins DEVD assay A.HEK293(pVac1-
rCasp3V266ED3) total cell proteins has signficant difference in DEVD activity when compared 
with HEK293 (pVac1-MCS) cell proteins. B. Caspase-3 westernblot on DEVD activity 
measured samples; 1,2,3- HEK293 (pVac1-MCS) cell protein replicates; 4,5,6- HEK293(pVac1-
rCasp3V266ED3) total cell protein replicates. There is no difference in thickness of caspase-3 
bands between two groups (qualitative observation).  
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 Figure 4-9 rCasp3V266ED3 membrane expression and activity confirmation on pVac1-
rCasp3V266ED3 transfected HEK293 cells 
A. pVac1-rCasp3V266ED3 transfected HEK293 cells membranes proteins have increased 
DEVD activity when compared with HEK293 or HEK293 (pVac1-MCS) membrane proteins. B. 
Caspase 3 westernblot on DEVD activity analyzed membrane protein samples; (1,2)- HEK293 
cells membrane protein replicates, (3,4)- HEK293 (pVac1-MCS) cells membrane protein 
replicates, (5,6)- HEK293 (pVac1-rCasp3V266ED3) cells membrane protein replicates. 
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 Figure 4-10 rhUPA or PI-PLC treatment on HEK293 cells transfected with pVac1-
rMcherryred plasmid 
A. pVac1-rMcherryred transfected HEK293 cells were treated with rhUPA and supernatant 
fluorescence intensity was measured and plotted. There is no difference in fluorescence intensity 
between rhUPA treated and untreated samples, Same pattern was observed with higher cell 
numbers (B). C. pVac1-rMcherryred transfected HEK293 cells were treated with PI-PLC and 
supernatant fluorescence intensity was measured and plotted. There is no difference in 
fluorescence intensity between PI-PLC treated and untreated samples, Same pattern was 
observed with higher cell numbers 
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Figure 4-11 rCasp3V266ED3 expression mediated toxicity on PC3 cells 
There is no significant difference in pVac1-rCasp3V266ED3 transfected PC3 cell viability when 
compared control (pVac1-rMcherryred transfected PC3 cells).  
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Figure 4-12 rMcherry red protein expression level difference between plasmids with 
different promoters 
A.HEK293 cells transfected with plasmid containing rMcherry red gene under rhEF1 promoter, 
B. HEK293 cells transfected with plasmid containing rMcherry red gene under CMV promoter 
(Inlets are showing mcherry red fluorescence). 
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 Abstract 
Animal models for cancer therapy are invaluable for preclinical testing of potential 
cancer treatments; however, therapies tested in such models often fail to translate into clinical 
settings. Therefore, a better preclinical model for cancer treatment testing is needed. Here we 
demonstrate that an immunodeficient line of pigs can host and support the growth of xenografted 
human tumors and has the potential to be an effective animal model for cancer therapy. Wild-
type and immunodeficient pigs were injected subcutaneously in the left ear with human 
melanoma cells (A375SM cells) and in the right ear with human pancreatic carcinoma cells 
(PANC-1). All immunodeficient pigs developed tumors that were verified by histology and 
immunohistochemistry. Nonaffected littermates did not develop tumors. Immunodeficient pigs, 
which do not reject xenografted human tumors, have the potential to become an extremely useful 
animal model for cancer therapy because of their similarity in size, anatomy, and physiology to 
humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
 Introduction 
Preclinical research on animal models is essential in developing and evaluating cancer 
therapeutics [170]. Syngeneic, xenograft, and genetically engineered mouse models have been 
developed to study cancer and cancer drug development [171]. Mouse xenograft models are used 
extensively in preclinical studies because of their relatively good correlation with human clinical 
data, as compared to other animal models [172-174]. However, studies on these mouse models 
often fail to accurately predict the response to and the effect of anticancer agents in human 
patients [172-174]. Ninety percent of new anticancer drugs that showed antitumor efficacy in 
mouse-based preclinical studies failed in human clinical studies [173, 174]. Several methods of 
overcoming this shortfall have been proposed, including genetically engineered transgenic 
mouse models and orthotopic xenograft models [175, 176], but these have yet to demonstrate 
significant improvements in translatability [175].Thus, there is a tremendous demand for more 
sophisticated animal models, which may improve the translation efficiency from preclinical to 
clinical studies. 
Pigs are large animals with similar anatomy and physiology to humans and have been 
used in many research areas [177]. The higher sequence homology of pigs with human 
xenobiotic receptors may allow more accurate prediction of pharmacodynamic and 
pharmacokinetic properties of drugs compared with mice [178]. Several attempts have been 
made to establish porcine tumor models in pigs as a treatment model for human cancers, for 
example, investigating spontaneous myelogenous leukemias [179], developing transplantable 
hematologic tumors [180], and genetically inducing tumorigenesis [181]. 
A xenograft model of human tumors in pigs would be an excellent model. Xenograft 
models of human tumors are often used in severe combined immunodeficiency (SCID) mice, 
which have severe lymphopenia due to defects in a DNA-dependent protein kinase gene that 
prevents variable–diversity–joining [V(D)J] gene region recombination [182]. The severe 
lymphopenia prevents SCID mice from rejecting human tumors. SCID-associated severe 
lymphopenia is also known in other species, notably humans. Several genetic defects have been 
identified in humans as causing SCID, including defects in adenylate kinase 2, adenosine 
deaminase, purine nucleoside phosphorylase, interleukin (IL)-2 receptor γ, Janus kinase 3, and 
the IL-7 receptor [183]. We recently identified pigs that are severely immunocompromised 
76 
 
(SCID-like pigs) (research paper not published yet). Yorkshire pigs bred for increased feed 
efficiency were noted to exhibit SCID-like symptoms. Further analysis of these pigs showed 
extremely decreased levels of lymphocytes in circulation and significantly atrophied thymus and 
lymph nodes. The mode of inheritance appears to be simple autosomal recessive, although the 
actual mutation remains to be elucidated. In the present study, we show evidence that these pigs 
can be used as human xenograft tumor models. As proof of concept, human melanoma cells 
(A375SM, amelanotic melanoma) and human pancreatic carcinoma cells (PANC-1) were 
transplanted subcutaneously into immunodeficient pigs, and the tumor-forming ability of the 
neoplastic cells was evaluated. 
 Materials and Methods 
 Reagents and cells 
PANC-1 cells and A375SM cells were purchased from ATCC (Manassas, VA). 
Dulbecco's Modified Eagle's Medium (DMEM) and penicillin (10,000 units/mL)/streptomycin 
(10,000 μg/mL) were purchased from Life Technologies (Grand Island, NY). Fetal bovine serum 
(FBS), hematoxylin, eosin, Tris–hydrochloride, and ethylenediaminetetraacetic acid (EDTA) 
were purchased from Sigma-Aldrich (St. Louis, MO). Antimitochondrial clone 113-1 (mouse 
anti-human mitochondrial antibody) was purchased from Millipore (Temecula, CA). Bond 
Polymer Refine Red detection kit, Bond Primary Antibody Diluent, and alkaline phosphatase-
conjugated Poly-AP anti-mouse antibody were purchased from Leica Microsystems (Buffalo 
Grove, IL). Fatal-plus (pentobarbital sodium) was obtained from Vortech Pharmaceuticals 
(Dearborn, MI). Banamine (flunixin meglumine) was obtained from Merck Animal 
Health/Intervet (Summit, NJ). Excenel (ceftiofur HCl) was obtained from Pfizer Animal Health 
(New York, NY). Second Bite Medicated feed with Tiamulin (35 g/ton) and chlortetracycline 
(400 g/ton) was purchased from Key Feeds, Fourth and Pomeroy Associates (Clay Center, KS). 
 Pig care 
Six littermate pigs (6 weeks of age, two male and four female) were obtained from Iowa 
State University from a boar and a sow that have been identified as carriers of the 
immunodeficiency gene. Pigs were identified at 2 weeks of age as likely to be immunodeficient 
or immunocompetent based on lymphocyte counts: values were 1.08, 1.22, and 1.81×10
3
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lymphocytes/μL for pigs expected to be immunodeficient (n=3, one male, two female) and 3.08, 
4.13, and 5.18×10
3
 lymphocytes/μL for presumed immunocompetent pigs (n=3, one male, two 
female). Pigs were transported to the Kansas State University at 6 weeks of age. Pigs were 
housed in a clean environment in raised pens upon arrival; however, neither the previous housing 
nor transportation was aseptic. Two days after arrival, blood samples were collected from the 
pigs to confirm the status of each pig by immunophenotyping. After confirmation of the immune 
status, the immunodeficient pigs were separated from the immunocompetent pigs in two 
different rooms in a clean environment in raised pens. Pigs were kept on a medicated diet and 
monitored daily for health status; ceftiofur HCl (2.2 mg/kg) and flunixin meglumine (1.1 mg/kg) 
were administered intramuscularly as indicated by veterinary consultation. 
 Xenograft tumor injection 
A375SM cells and PANC-1 cells were cultured in the DMEM with 10% FBS and 1% 
penicillin/streptomycin. PANC-1 and A375SM cells were lifted, counted, and concentrated to 40 
million cells/mL in PBS. Pigs were anesthetized by administration of isoflurane gas vaporized 
into oxygen (1–5%) and delivered via a face mask. 100 μL (4 million cells) of the PANC-1 cell 
suspension was injected subcutaneously into the right ear by tenting the skin of the ear near the 
base; 100 μL (4 million cells) of the A375SM cell suspension was injected subcutaneously into 
the left ear by tenting the skin of the ear near the base. After injecting, the pigs were removed 
from anesthesia and observed until reaching sternal recumbency. 
After tumor injection, the pigs were monitored daily for tumor growth. Both right and left 
ears were visually inspected and palpated to determine presence of tumors daily. Once tumors 
were identified, calipers were used to measure the tumor size. 
 Histopathology and immunohistochemistry 
Immunocompromised pigs were monitored for signs of respiratory disease, which often 
occurs because of the immunocompromised status. When a serious disease presented, the pigs 
were euthanized using Fatal-plus (days 6, 14, and 22). Unaffected littermates were euthanized 
with the last immunocompromised pig at day 22. At euthanasia, ear tissue was collected and 
fixed in 10% buffered formalin, processed routinely for sectioning, and then stained with 
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hematoxylin and eosin (H&E). H&E sections were evaluated for histological evidence of tumors. 
For immunohistochemical analysis, unstained paraffin-embedded tissue was probed with anti-
human mitochondrial antibody. Tissues were stained using the Leica Bond-Max automatic 
stainer (Leica Microsystems) with the Bond Polymer Refine Red detection kit. Tissues were 
pretreated for 20 min with Tris–EDTA (pH 9.0) for antigen retrieval. The primary antibody was 
diluted 1:100 using Bond Primary Antibody Diluent. Tissues were then stained with the primary 
antibody for 15 min followed by a secondary antibody (Powervision Poly-AP Anti-Mouse) for 
25 min. Antibody-probed tissues were then counterstained with hematoxylin. Antibody-probed 
sections were evaluated for positive staining, indicating the presence of human cells. 
 Results 
 Pig observations 
No visible tumor growth was noted at day 6 when the first immunodeficient pig (pig 1) 
was euthanized. On day 13, a small, firm, very slightly raised, elongated white mass was 
identified visually and by palpation on the left ear (amelanotic melanoma) of pig 2, but was too 
small to measure with the caliper. Pig 2 was euthanized on day 14. On day 14, a similar small, 
firm, raised, elongated white mass was identified on the left ear of pig 3, but was too small to 
measure with the caliper. On day 20, gross photographs were taken of the mass (Figure 5-1). On 
day 22, pig 3 was euthanized. At postmortem examination, the tumor in the left ear (melanoma) 
was dissected free from the skin and measured 10.3×5.5 mm. No grossly discernible tumors were 
observed in the right ears (pancreatic carcinoma) of any of the immunodeficient pigs. No grossly 
discernible tumors were observed in either ear in the wild-type pigs. 
 Histopathology and immunohistochemistry 
Histology and immunohistochemistry revealed the presence of tumors in all injection 
sites for both tumors in SCID-like pigs. Pig 1 showed small tumors in both the right ear (Figure 
5-2A) and the left ear (Figure 5-3A) histologically, indicating the lack of rejection of both the 
PANC-1 and the ASM375 cells. These tumors were verified by strong positive cytoplasmic 
staining with anti-human mitochondrial antibody (Figure 5-2 B,C and Figure 5-3B,C). Pig 2 also 
showed tumors in both the right ear (Figure 5-2D) and the left ear (Figure 5-3D) histologically, 
which were verified by positive immunostaining (Figure 5-2 E,F and Figure 5-3 E,F). Pig 3 also 
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showed tumors in both the right ear and the left ear that were substantially larger than the tumors 
of pigs 1 and 2. These tumors were also identified histologically and verified by positive staining 
with anti-human mitochondrial antibody (Figure 5-2G-I and Figure 5-3G-I). 
All six tumor sites showed characteristic histologic features of malignant neoplasia, 
including bizarre and atypical mitotic figures and prominent anisocytosis and anisokaryosis 
(Figure 5-4). No tumors were identified histologically in the ears of wild-type pigs (Figure 5-5), 
consistent with expected rejection of human origin cells by pigs with intact immune systems. 
Full histopathological descriptions of the tumors of each immunodeficient pig are as follows 
Pig 1 
Right ear- Focally within the subcutis is a small, unencapsulated, well-demarcated neoplasm 
composed of nests and packets of neoplastic cells on a ﬁne ﬁbrovascular stroma. Neoplastic 
cells are polygonal, with variably distinct cell borders and moderate-to-large amounts of pale 
eosinophilic vacuolated cytoplasm. Nuclei are round to oval to irregular and vesicular, with 
generally 1–3 prominent magenta nucleoli. Anisocytosis and anisokaryosis are moderate, and 
mitoses are 8 in 10 high-power ﬁelds (hpf) and occasionally bizarre. At the periphery of the 
neoplasm, adjacent to a small vessel, are small numbers of lymphocytes. 
Left ear - Within the deep dermis, subcutis, and skeletal muscle, there is an unencapsulated, 
moderately demarcated and inﬁltrative neoplasm composed of nests and short streams of 
neoplastic cells on a scant ﬁbrovascular stroma. Neoplastic cells are polygonal to spindloid, with 
indistinct cell borders and a small-to-moderate amount of vacuolated eosinophilic cytoplasm. 
Nuclei are oval to irregular, with ﬁnely stippled chromatin and 1–2 variably prominent nucleoli. 
Anisocytosis and anisokaryosis are mild, and mitoses are 4 in 10 hpf. 
Pig 2 
Right ear- Within the subcutis and skeletal muscle, there is an unencapsulated, moderately 
demarcated and mildly inﬁltrativeneoplasm composed of nests and packets of neoplastic cells 
on a ﬁne ﬁbrovascular stroma. Neoplastic cells are polygonal, with variably distinct cell borders 
and moderate-to-large amounts of pale eosinophilic vacuolated cytoplasm. Nuclei are round to 
oval to irregular and vesicular, with one generally prominent magenta nucleolus. Anisocytosis 
and anisokaryosis are mild to moderate, and mitoses are 1 in 10 hpf. The neoplasm is surrounded 
by small numbers of lymphocytes and rare plasma cells. 
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Left ear- Within the deep dermis and subcutis, and extending into the adjacent skeletal muscle, 
is an unencapsulated, moderately demarcated and mildly inﬁltrative neoplasm composed of nests 
and short streams of neoplastic cells within a moderate amount of ﬁbrovascular stroma. 
Neoplastic cells are polygonal to spindloid, with indistinct cell borders and a small amount of 
vacuolated eosinophilic cytoplasm. Nuclei are round to oval to irregular, with ﬁnely stippled 
chromatin and 1–2 variably prominent nucleoli. Anisocytosis and anisokaryosis are moderate, 
and mitoses are 4–7 per hpf and often bizarre. 
Pig 3 
Right ear-Within the dermis, subcutis, and skeletal muscle, there is anunencapsulated, poorly 
demarcated and inﬁltrative neoplasm composed of nests and packets of neoplastic cells on a ﬁne 
ﬁbrovascular stroma. Neoplastic cells are polygonal, with variably distinct cell borders and a 
small to moderate of pale eosinophilic-to-amphophilic vacuolated cytoplasm. Nuclei 
are round to oval to irregular and vesicular, with one-tomultiple variably prominent nucleoli. 
Anisocytosis and anisokaryosis are moderate, and mitoses are <1 in 10 hpf. 
Left ear- The deep dermis and subcutis contain an unencapsulated, moderately demarcated 
neoplasm composed of densely packed nests and short streams of neoplastic cells within a 
moderate amount of ﬁbrovascular stroma. Neoplastic cells are polygonal to spindloid, with 
indistinct cell borders and a small amount of vacuolated eosinophilic cytoplasm. Nuclei are 
round to oval to irregular, with ﬁnely stippled chromatin and 1–2 variably prominent nucleoli. 
Anisocytosis and anisokaryosis are moderate, and mitoses are 2–5 per hpf and often bizarre. 
 Discussion 
A large-animal model of human tumors that closely mimics the size, anatomy, and 
physiology of humans would be of great value to cancer research. Here we have demonstrated 
that a naturally occurring immunodeficient line of pigs is capable of hosting xenograft human 
cells and developing active human tumors. It is possible that immunodeficient pigs fail to reject 
human xenograft tumors due to their low levels of lymphocytes, but immunodeficient pigs do not 
fail to produce all lymphocytes. Preliminary results indicate that the lymphocytes present in 
immunodeficient pigs do not express CD3, CD4, CD8, CD21, or CD79a. This may indicate that 
the remaining cells are natural killer (NK) cells that may not be functional due to lack of T-cell-
associated cytokine stimulation. Therefore, there may be no functional lymphocytes that would 
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be able to reject the human tumor xenograft. Further studies are being done on the lymphocyte 
profiles in the immunodeficient pigs. 
The melanoma model described here is orthotopic; the subcutaneous model of pancreatic 
adenocarcinoma, however, is not orthotopic. For this study, the proof of concept that 
immunodeficient pigs would not reject tumors was demonstrated using an easily monitored 
tumor location. In the future, orthotopic models of pancreatic cancer may be explored in these 
pigs to determine their suitability for investigating this devastating human cancer. 
One of the major problems with current animal models for human tumors is the low 
translatability to clinical settings [174]. This is often due to the limited similarity in anatomy and 
physiology of common tumor models such as SCID mice [172, 174]. Because pig anatomy and 
physiology are very similar to that of humans, the immunodeficient pig tumor model could be 
used for testing multiple types of cancer therapy, including chemotherapy, radiotherapy, and 
surgical reduction, with more realistic results. Therefore, this model has the potential to be a 
valuable human cancer model for preclinical cancer research, with a high rate of translatability to 
the clinical settings. 
The usefulness of this model may not be limited to cancer therapy. Since the 
immunodeficient pigs do not reject xenografts, they may be a useful model for other disease 
states as well. For example, human liver cell xenografts could be grown in pigs and then infected 
with hepatitis B or C for testing various antiviral medications. Similarly, the pigs could be 
reconstituted with primitive human hematopoietic stem cells (e.g., cord blood) to generate a pig 
chimera with a human immune system, a useful model for studies such as human 
immunodeficiency virus antiviral therapies. Thus, a pig model that does not reject human 
xenografts is a unique animal model with potential uses in a variety of preclinical applications 
for human health. 
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Figure 5-1 Antemortem visual evidence of tumor growth in pig 3 (day 20) 
A. Photograph indicated a large growth on the left ear, B. Same photograph as in (A), with the 
growth outlined for visual reference. 
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Figure 5-2 Right ear with pancreatic carcinoma cells from pigs euthanized at day-6,14,22  
post-transplantation 
 A. There is a focal, well-demarcated, unencapsulated neoplasm composed of nests and packets 
of neoplastic cells within the subcutis. B, C Strong positivity to anti-human mitochondrial 
antibody is evident within the cytoplasm of neoplastic cells. D Within the 
subcutis and skeletal muscle, there is an unencapsulated, moderately demarcated, and mildly 
inﬁltrative neoplasm composed of nests and packets of neoplastic cells. E, F Strong positivity to 
anti-human mitochondrial antibody is evident within the cytoplasm of neoplastic cells. G Within 
the dermis, subcutis, and skeletal muscle, there is an unencapsulated, poorly demarcated, and 
inﬁltrative neoplasm composed of nests and packets of neoplastic cells. H, I Strong positivity to 
anti-human mitochondrial antibody is evident within the cytoplasm of neoplastic cells. (A, D, G) 
H&E stain; (B, C, E, F, H, I) anti-humanmitochondrial antibody immunohistochemistry. H&E, 
hematoxylin and eosin. 
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Figure 5-3 Left ear with melanoma cells from pigs euthanized at day 6, 14, and 22 post-
transplantation 
 (A) Within the deep dermis, subcutis, and skeletal muscle, there is an unencapsulated and 
inﬁltrative neoplasm composed of nests and short streams of neoplastic cells. (B, C) Strong 
positivity to anti-human mitochondrial antibody is evident within the cytoplasm of neoplastic 
cells. (D) Within the deep dermis and subcutis, there is an unencapsulated and inﬁltrative 
neoplasm composed of nests and short streams of neoplastic cells within a moderate amount of 
ﬁbrovascular stroma. (E, F) Strong positivity to anti-human mitochondrial antibody is evident 
within the cytoplasm of neoplastic cells. (G)Within the deep dermis and subcutis, there is an 
unencapsulated, moderately demarcated, and inﬁltrative neoplasm composed of nests and short 
streams of neoplastic cells within a moderate amount of ﬁbrovascular stroma. (H, I) Strong 
positivity to anti-human mitochondrial antibody is evident within the cytoplasm of neoplastic 
cells.(A, D, G) H&E stain;(B, C, E, F, H, I) anti-human mitochondrial antibody 
immunohistochemistry. 
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Figure 5-4 Photomicrographs of the left ear of pig 3 demonstrating histologic features of 
neoplasia 
 (A) Note multiple mitotic ﬁgures. (B) Note signiﬁcant cellular and nuclear pleomorphism. 
H&E stain. 
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Figure 5-5 Wild type pigs ears histological analysis 
Right ear (A) and left ear (B) from control pigs at day 22. No tumors were identiﬁed at the site of 
injection ofhuman-origin neoplastic cells. H&E stain. 
 
 
  
87 
 
References  
1. World health organization Cancer key facts.  2008  [cited; Available from: 
http://www.who.int/mediacentre/factsheets/fs297/en/. 
2. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell. 144(5): 
p. 646-74. 
3. Hornberg, J.J., et al., Cancer: a Systems Biology disease. Biosystems, 2006. 83(2-3): p. 
81-90. 
4. Weinberg, R.A., The biology of Cancer. 2 ed. 2013: Garland sciences. 
5. Hanahan, D. and L.M. Coussens, Accessories to the crime: functions of cells recruited to 
the tumor microenvironment. Cancer Cell. 21(3): p. 309-22. 
6. DeVita, V.T., Jr. and S.A. Rosenberg, Two hundred years of cancer research. N Engl J 
Med. 366(23): p. 2207-14. 
7. Mukherjee, S., The Emperor of All Maladies: A Biography of Cancer. 2011. 
8. Fischbach, M.A., J.A. Bluestone, and W.A. Lim, Cell-based therapeutics: the next pillar 
of medicine. Sci Transl Med. 5(179): p. 179ps7. 
9. Studeny, M., et al., Mesenchymal stem cells: potential precursors for tumor stroma and 
targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst, 2004. 96(21): p. 
1593-603. 
10. Aboody, K.S., et al., Development of a tumor-selective approach to treat metastatic 
cancer. PLoS One, 2006. 1: p. e23. 
11. Keung, E.Z., P.J. Nelson, and C. Conrad, Concise review: genetically engineered stem 
cell therapy targeting angiogenesis and tumor stroma in gastrointestinal malignancy. 
Stem Cells. 31(2): p. 227-35. 
12. Aboody, K.S., et al., Neural stem cells display extensive tropism for pathology in adult 
brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A, 2000. 97(23): p. 
12846-51. 
13. Muthana, M., et al., Use of macrophages to target therapeutic adenovirus to human 
prostate tumors. Cancer Res. 71(5): p. 1805-15. 
14. Eisenstein, S., et al., Myeloid-derived suppressor cells as a vehicle for tumor-specific 
oncolytic viral therapy. Cancer Res. 73(16): p. 5003-15. 
15. Su, W., et al., Human Embryonic Stem Cell-Derived Endothelial Cells as Cellular 
Delivery Vehicles for Treatment of Metastatic Breast Cancer. Cell Transplant. 
16. Dranoff, G., Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer, 
2004. 4(1): p. 11-22. 
17. Using mesenchymal stem cells to home in and deliver anti-tumor therapy with interferon-
beta. Cancer Biol Ther, 2004. 3(12): p. 1192. 
18. Seo, K.W., et al., Anti-tumor effects of canine adipose tissue-derived mesenchymal 
stromal cell-based interferon-beta gene therapy and cisplatin in a mouse melanoma 
model. Cytotherapy. 13(8): p. 944-55. 
19. Sims, T.L., Jr., et al., Neural progenitor cell-mediated delivery of interferon beta 
improves neuroblastoma response to cyclophosphamide. Ann Surg Oncol, 2008. 15(11): 
p. 3259-67. 
20. Aboody, K.S., J. Najbauer, and M.K. Danks, Stem and progenitor cell-mediated tumor 
selective gene therapy. Gene Ther, 2008. 15(10): p. 739-52. 
88 
 
21. Li, X., et al., In vitro effect of adenovirus-mediated human Gamma Interferon gene 
transfer into human mesenchymal stem cells for chronic myelogenous leukemia. Hematol 
Oncol, 2006. 24(3): p. 151-8. 
22. Duan, X., et al., Murine bone marrow-derived mesenchymal stem cells as vehicles for 
interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer, 2009. 115(1): p. 13-22. 
23. Elzaouk, L., K. Moelling, and J. Pavlovic, Anti-tumor activity of mesenchymal stem cells 
producing IL-12 in a mouse melanoma model. Exp Dermatol, 2006. 15(11): p. 865-74. 
24. Gao, P., et al., Therapeutic potential of human mesenchymal stem cells producing IL-12 
in a mouse xenograft model of renal cell carcinoma. Cancer Lett. 290(2): p. 157-66. 
25. Barti-Juhasz, H., et al., Bone marrow derived mesenchymal stem/stromal cells transduced 
with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro. 
Haematologica. 96(3): p. e21-2. 
26. Choi, S.A., et al., Therapeutic efficacy and safety of TRAIL-producing human adipose 
tissue-derived mesenchymal stem cells against experimental brainstem glioma. Neuro 
Oncol. 13(1): p. 61-9. 
27. Kim, S.M., et al., Gene therapy using TRAIL-secreting human umbilical cord blood-
derived mesenchymal stem cells against intracranial glioma. Cancer Res, 2008. 68(23): 
p. 9614-23. 
28. Kim, S.M., et al., Effective combination therapy for malignant glioma with TRAIL-
secreting mesenchymal stem cells and lipoxygenase inhibitor MK886. Cancer Res. 
72(18): p. 4807-17. 
29. Lee, H.J., et al., A therapeutic strategy for metastatic malignant fibrous histiocytoma 
through mesenchymal stromal cell-mediated TRAIL production. Ann Surg. 257(5): p. 
952-60. 
30. Menon, L.G., et al., Human bone marrow-derived mesenchymal stromal cells expressing 
S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells, 2009. 
27(9): p. 2320-30. 
31. Moniri, M.R., et al., TRAIL-engineered pancreas-derived mesenchymal stem cells: 
characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther. 
19(9): p. 652-8. 
32. Nesterenko, I., et al., Evaluating the effect of therapeutic stem cells on TRAIL resistant 
and sensitive medulloblastomas. PLoS One. 7(11): p. e49219. 
33. Zhang, B., et al., The inhibitory effect of MSCs expressing TRAIL as a cellular delivery 
vehicle in combination with cisplatin on hepatocellular carcinoma. Cancer Biol Ther. 
13(12): p. 1175-84. 
34. Xu, G., et al., Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells 
effectively suppresses the growth of glioma in rats. Cell Biol Int, 2009. 33(4): p. 466-74. 
35. Xin, H., et al., Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal 
stem cells. Stem Cells, 2007. 25(7): p. 1618-26. 
36. Xin, H., et al., Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to 
multiple lung tumors. Mol Med, 2009. 15(9-10): p. 321-7. 
37. Azrak, R.G., et al., Therapeutic synergy between irinotecan and 5-fluorouracil against 
human tumor xenografts. Clin Cancer Res, 2004. 10(3): p. 1121-9. 
38. Friedlos, F., et al., Mustard prodrugs for activation by Escherichia coli nitroreductase in 
gene-directed enzyme prodrug therapy. J Med Chem, 1997. 40(8): p. 1270-5. 
89 
 
39. Greco, O. and G.U. Dachs, Gene directed enzyme/prodrug therapy of cancer: historical 
appraisal and future prospectives. J Cell Physiol, 2001. 187(1): p. 22-36. 
40. Altaner, C. and V. Altanerova, Stem cell based glioblastoma gene therapy. Neoplasma. 
59(6): p. 756-60. 
41. Matuskova, M., et al., HSV-tk expressing mesenchymal stem cells exert bystander effect 
on human glioblastoma cells. Cancer Lett. 290(1): p. 58-67. 
42. Ryu, C.H., et al., Valproic acid enhances anti-tumor effect of mesenchymal stem cell 
mediated HSV-TK gene therapy in intracranial glioma. Biochem Biophys Res Commun. 
421(3): p. 585-90. 
43. Choi, S.A., et al., Human adipose tissue-derived mesenchymal stem cells: characteristics 
and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem 
gliomas. Eur J Cancer. 48(1): p. 129-37. 
44. Basel, M.T., et al., A cell-delivered and cell-activated SN38-dextran prodrug increases 
survival in a murine disseminated pancreatic cancer model. Small. 8(6): p. 913-20. 
45. Seo, G.M., et al., A self-contained enzyme activating prodrug cytotherapy for preclinical 
melanoma. Mol Biol Rep. 39(1): p. 157-65. 
46. Kim, S.W., et al., Complete regression of metastatic renal cell carcinoma by multiple 
injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and 
HSV-TK. Clin Cancer Res. 19(2): p. 415-27. 
47. Rachakatla, R.S., et al., Combination treatment of human umbilical cord matrix stem cell-
based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of 
metastatic human breast cancer in SCID mouse lungs. Cancer Invest, 2008. 26(7): p. 
662-70. 
48. Scott, A.M., J.D. Wolchok, and L.J. Old, Antibody therapy of cancer. Nat Rev Cancer. 
12(4): p. 278-87. 
49. Frank, R.T., et al., Neural stem cells as a novel platform for tumor-specific delivery of 
therapeutic antibodies. PLoS One, 2009. 4(12): p. e8314. 
50. Willmon, C., et al., Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol 
Ther, 2009. 17(10): p. 1667-76. 
51. Sonabend, A.M., et al., Oncolytic adenoviral therapy for glioblastoma multiforme. 
Neurosurg Focus, 2006. 20(4): p. E19. 
52. Ahmed, A.U., et al., A comparative study of neural and mesenchymal stem cell-based 
carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm. 8(5): p. 
1559-72. 
53. Schnarr, K., et al., Gold nanoparticle-loaded neural stem cells for photothermal ablation 
of cancer. Adv Healthc Mater. 2(7): p. 976-82. 
54. Matsui, M., et al., Targeted delivery of oligomannose-coated liposome to the omental 
micrometastasis by peritoneal macrophages from patients with gastric cancer. Cancer 
Sci. 101(7): p. 1670-7. 
55. Knoop, K., et al., Image-guided, tumor stroma-targeted 131I therapy of hepatocellular 
cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. Mol Ther. 
19(9): p. 1704-13. 
56. Shrestha, T.B., et al., Stem cell-based photodynamic therapy. Photochem Photobiol Sci. 
11(7): p. 1251-8. 
57. Dranoff, G., S. Grupp, and C. June, Adoptive Cellular Therapy, in Cancer Immunology 
and Immunotherapy, Springer Berlin Heidelberg. p. 149-172. 
90 
 
58. van der Zee, J., Heating the patient: a promising approach? Ann Oncol, 2002. 13(8): p. 
1173-84. 
59. Kumar, C.S.S.R. and F. Mohammad, Magnetic nanomaterials for hyperthermia-based 
therapy and controlled drug delivery. Advanced Drug Delivery Reviews. 63(9): p. 789-
808. 
60. Giovanella, B.C. and B. Mondovi, Selective heat sensitivity of cancer cells: Introduction. 
Recent Results Cancer Res, 1977(59): p. 1-6. 
61. Dewey, W.C., Interaction of heat with radiation and chemotherapy. Cancer Res, 1984. 
44(10 Suppl): p. 4714s-4720s. 
62. Tschoep-Lechner, K.E., et al., Gemcitabine and cisplatin combined with regional 
hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced 
pancreatic cancer. Int J Hyperthermia. 29(1): p. 8-16. 
63. Zhao, C., C. Dai, and X. Chen, Whole-body hyperthermia combined with hyperthermic 
intraperitoneal chemotherapy for the treatment of stage IV advanced gastric cancer. Int J 
Hyperthermia. 28(8): p. 735-41. 
64. Hurwitz, M.D., et al., Hyperthermia combined with radiation for the treatment of locally 
advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 
94-153. Cancer. 117(3): p. 510-6. 
65. Hurwitz, M.D., et al., Hyperthermia combined with radiation in treatment of locally 
advanced prostate cancer is associated with a favourable toxicity profile. Int J 
Hyperthermia, 2005. 21(7): p. 649-56. 
66. Zhu, J., et al., [Hyperthermia combined with chemotherapy in the treatment of advanced 
non-small cell lung cancer: an initial study]. Zhongguo Fei Ai Za Zhi, 2005. 8(4): p. 
326-8. 
67. Ben-Yosef, R., et al., Hyperthermia combined with radiation therapy in the treatment of 
local recurrent breast cancer. Isr Med Assoc J, 2004. 6(7): p. 392-5. 
68. Gofrit, O.N., et al., Combined local bladder hyperthermia and intravesical chemotherapy 
for the treatment of high-grade superficial bladder cancer. Urology, 2004. 63(3): p. 466-
71. 
69. Wust, P., et al., Hyperthermia in combined treatment of cancer. Lancet Oncol, 2002. 
3(8): p. 487-97. 
70. Hildebrandt, B., et al., The cellular and molecular basis of hyperthermia. Crit Rev Oncol 
Hematol, 2002. 43(1): p. 33-56. 
71. Orgill, D.P., S.A. Porter, and H.O. Taylor, Heat injury to cells in perfused systems. Ann 
N Y Acad Sci, 2005. 1066: p. 106-18. 
72. Song, C.W., et al., Improvement of tumor oxygenation status by mild temperature 
hyperthermia alone or in combination with carbogen. Semin Oncol, 1997. 24(6): p. 626-
32. 
73. Subjeck, J.R., et al., Heat shock proteins and biological response to hyperthermia. Br J 
Cancer Suppl, 1982. 5: p. 127-31. 
74. Ito, A., et al., Antitumor effects of combined therapy of recombinant heat shock protein 
70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous 
murine melanoma. Cancer Immunol Immunother, 2004. 53(1): p. 26-32. 
75. Li, Z., A. Menoret, and P. Srivastava, Roles of heat-shock proteins in antigen 
presentation and cross-presentation. Curr Opin Immunol, 2002. 14(1): p. 45-51. 
91 
 
76. Srivastava, P., Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev 
Immunol, 2002. 2(3): p. 185-94. 
77. Jordan, A., et al., Presentation of a new magnetic field therapy system for the treatment of 
human solid tumors with magnetic fluid hyperthermia. Journal of Magnetism and 
Magnetic Materials, 2001. 225(1â€“2): p. 118-126. 
78. Jordan, A., et al., Inductive heating of ferrimagnetic particles and magnetic fluids: 
physical evaluation of their potential for hyperthermia. 1993. Int J Hyperthermia, 2009. 
25(7): p. 499-511. 
79. Kumar, C.S. and F. Mohammad, Magnetic nanomaterials for hyperthermia-based 
therapy and controlled drug delivery. Adv Drug Deliv Rev. 63(9): p. 789-808. 
80. Chatterjee, D.K., P. Diagaradjane, and S. Krishnan, Nanoparticle-mediated hyperthermia 
in cancer therapy. Ther Deliv. 2(8): p. 1001-14. 
81. Kottitz, R., P.C. Fannin, and L. Trahms, Time domain study of Brownian and NÃ©el 
relaxation in ferrofluids. Journal of Magnetism and Magnetic Materials, 1995. 
149(1â€“2): p. 42-46. 
82. Pakhomov, A.B., Y. Bao, and K.M. Krishnan, Effects of surfactant friction on Brownian 
magnetic relaxation in nanoparticle ferrofluids. Journal of Applied Physics, 2005. 
97(10): p. 10Q305-3. 
83. Mornet, S., et al., Magnetic nanoparticle design for medical diagnosis and therapy. 
Journal of Materials Chemistry, 2004. 14(14): p. 2161-2175. 
84. Huber, D.L., Synthesis, properties, and applications of iron nanoparticles. Small, 2005. 
1(5): p. 482-501. 
85. Gordon, R.T., J.R. Hines, and D. Gordon, Intracellular hyperthermia. A biophysical 
approach to cancer treatment via intracellular temperature and biophysical alterations. 
Med Hypotheses, 1979. 5(1): p. 83-102. 
86. Xie, J., et al., Iron oxide nanoparticle platform for biomedical applications. Curr Med 
Chem, 2009. 16(10): p. 1278-94. 
87. Jordan, A., et al., The effect of thermotherapy using magnetic nanoparticles on rat 
malignant glioma. J Neurooncol, 2006. 78(1): p. 7-14. 
88. Jordan, A., et al., Effects of magnetic fluid hyperthermia (MFH) on C3H mammary 
carcinoma in vivo. Int J Hyperthermia, 1997. 13(6): p. 587-605. 
89. Huang, H.S. and J.F. Hainfield, Intravenous magnetic nanoparticle cancer hyperthermia. 
Int J Nanomedicine. 8: p. 2521-32. 
90. Balivada, S., et al., A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron 
oxide core/shell magnetic nanoparticles: a mouse study. BMC Cancer. 10: p. 119. 
91. Shecterle, L.M. and J.A. St Cyr, Whole body hyperthermia as a potential therapeutic 
option. Cancer Biother, 1995. 10(4): p. 253-6. 
92. Habash, R.W., et al., Thermal therapy, part 2: hyperthermia techniques. Crit Rev Biomed 
Eng, 2006. 34(6): p. 491-542. 
93. Hildebrandt, B., et al., Current status of radiant whole-body hyperthermia at 
temperatures >41.5 degrees C and practical guidelines for the treatment of adults. The 
German 'Interdisciplinary Working Group on Hyperthermia'. Int J Hyperthermia, 2005. 
21(2): p. 169-83. 
94. Jia, D. and J. Liu, Current devices for high-performance whole-body hyperthermia 
therapy. Expert Rev Med Devices. 7(3): p. 407-23. 
92 
 
95. Sminia, P., et al., Effect of hyperthermia on the central nervous system: a review. Int J 
Hyperthermia, 1994. 10(1): p. 1-30. 
96. Vertree, R.A., et al., Whole-body hyperthermia: a review of theory, design and 
application. Perfusion, 2002. 17(4): p. 279-90. 
97. Kraybill, W.G., et al., A phase I study of fever-range whole body hyperthermia (FR-
WBH) in patients with advanced solid tumours: correlation with mouse models. Int J 
Hyperthermia, 2002. 18(3): p. 253-66. 
98. Jia, D., et al., Inhibition of B16 murine melanoma metastasis and enhancement of 
immunity by fever-range whole body hyperthermia. Int J Hyperthermia. 27(3): p. 275-85. 
99. Ueno, S., P. Lovsund, and P.A. Oberg, Effects of alternating magnetic fields and low-
frequency electric currents on human skin blood flow. Med Biol Eng Comput, 1986. 
24(1): p. 57-61. 
100. Do weak alternating magnetic fields have biological effects? Public Health, 1982. 96(4): 
p. 189-90. 
101. Maier-Hauff, K., et al., Intracranial Thermotherapy using Magnetic Nanoparticles 
Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients 
with Glioblastoma Multiforme. Journal of Neuro-Oncology, 2007. 81(1): p. 53-60. 
102. Dilnawaz, F., et al., Dual drug loaded superparamagnetic iron oxide nanoparticles for 
targeted cancer therapy. Biomaterials. 31(13): p. 3694-706. 
103. Chen, Y., et al., Nanoparticles modified with tumor-targeting scFv deliver siRNA and 
miRNA for cancer therapy. Mol Ther. 18(9): p. 1650-6. 
104. Sugahara, K.N., et al., Tissue-penetrating delivery of compounds and nanoparticles into 
tumors. Cancer Cell, 2009. 16(6): p. 510-20. 
105. Sugahara, K.N., et al., Coadministration of a tumor-penetrating peptide enhances the 
efficacy of cancer drugs. Science. 328(5981): p. 1031-5. 
106. Gao, J., H. Gu, and B. Xu, Multifunctional magnetic nanoparticles: design, synthesis, 
and biomedical applications. Acc Chem Res, 2009. 42(8): p. 1097-107. 
107. Salloum, M., R. Ma, and L. Zhu, An in-vivo experimental study of temperature elevations 
in animal tissue during magnetic nanoparticle hyperthermia. Int J Hyperthermia, 2008. 
24(7): p. 589-601. 
108. Salloum, M., et al., Controlling nanoparticle delivery in magnetic nanoparticle 
hyperthermia for cancer treatment: experimental study in agarose gel. Int J 
Hyperthermia, 2008. 24(4): p. 337-45. 
109. Shinkai, M. and A. Ito, Functional magnetic particles for medical application. Adv 
Biochem Eng Biotechnol, 2004. 91: p. 191-220. 
110. Arbab, A.S., et al., Magnetic resonance imaging and confocal microscopy studies of 
magnetically labeled endothelial progenitor cells trafficking to sites of tumor 
angiogenesis. Stem Cells, 2006. 24(3): p. 671-8. 
111. De Palma, M., et al., Tumor-targeted interferon-alpha delivery by Tie2-expressing 
monocytes inhibits tumor growth and metastasis. Cancer Cell, 2008. 14(4): p. 299-311. 
112. Ganta, C., et al., Rat umbilical cord stem cells completely abolish rat mammary 
carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell 
inoculation. Cancer Res, 2009. 69(5): p. 1815-20. 
113. Nakamizo, A., et al., Human bone marrow-derived mesenchymal stem cells in the 
treatment of gliomas. Cancer Res, 2005. 65(8): p. 3307-18. 
93 
 
114. Rachakatla, R.S., et al., Development of human umbilical cord matrix stem cell-based 
gene therapy for experimental lung tumors. Cancer Gene Ther, 2007. 14(10): p. 828-35. 
115. Studeny, M., et al., Bone marrow-derived mesenchymal stem cells as vehicles for 
interferon-beta delivery into tumors. Cancer Res, 2002. 62(13): p. 3603-8. 
116. Wolf, D., et al., Re: Mesenchymal stem cells: potential precursors for tumor stroma and 
targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst, 2005. 97(7): p. 540-
1; author reply 541-2. 
117. Loebinger, M.R., et al., Magnetic resonance imaging of mesenchymal stem cells homing 
to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res, 2009. 
69(23): p. 8862-7. 
118. Kim, S.K., et al., Human neural stem cells target experimental intracranial 
medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin 
Cancer Res, 2006. 12(18): p. 5550-6. 
119. Ziu, M., et al., Glioma-produced extracellular matrix influences brain tumor tropism of 
human neural stem cells. J Neurooncol, 2006. 79(2): p. 125-33. 
120. Aboody, K.S., et al., Targeting of melanoma brain metastases using engineered neural 
stem/progenitor cells. Neuro Oncol, 2006. 8(2): p. 119-26. 
121. Ehtesham, M., et al., The use of interleukin 12-secreting neural stem cells for the 
treatment of intracranial glioma. Cancer Res, 2002. 62(20): p. 5657-63. 
122. Rachakatla, R.S., et al., Attenuation of mouse melanoma by A/C magnetic field after 
delivery of bi-magnetic nanoparticles by neural progenitor cells. ACS Nano. 4(12): p. 
7093-104. 
123. Ourednik, J., et al., Neural stem cells display an inherent mechanism for rescuing 
dysfunctional neurons. Nat Biotechnol, 2002. 20(11): p. 1103-10. 
124. Riemer, J., et al., Colorimetric ferrozine-based assay for the quantitation of iron in 
cultured cells. Anal Biochem, 2004. 331(2): p. 370-5. 
125. Shevchenko, A., et al., Mass spectrometric sequencing of proteins silver-stained 
polyacrylamide gels. Anal Chem, 1996. 68(5): p. 850-8. 
126. Tang, S.J., et al., Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce 
cyclooxygenase 2 expression and promote anti-tumor immunity in vivo. Int J Cancer, 
2008. 123(12): p. 2840-8. 
127. Wang, J., et al., Characterization of phosphoglycerate kinase-1 expression of stromal 
cells derived from tumor microenvironment in prostate cancer progression. Cancer Res. 
70(2): p. 471-80. 
128. Nakano, H., et al., TRAF5, an activator of NF-kappaB and putative signal transducer for 
the lymphotoxin-beta receptor. J Biol Chem, 1996. 271(25): p. 14661-4. 
129. Gibbs, P.E. and M.D. Maines, Biliverdin inhibits activation of NF-kappaB: reversal of 
inhibition by human biliverdin reductase. Int J Cancer, 2007. 121(11): p. 2567-74. 
130. Wu, K. and B. Bonavida, The activated NF-kappaB-Snail-RKIP circuitry in cancer 
regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. 
Critical reviews in immunology, 2009. 29(3): p. 241-254. 
131. Melle, C., et al., Identification of specific protein markers in microdissected 
hepatocellular carcinoma. J Proteome Res, 2007. 6(1): p. 306-15. 
132. Selga, E., V. Noe, and C.J. Ciudad, Transcriptional regulation of aldo-keto reductase 
1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle 
and apoptosis. Biochem Pharmacol, 2008. 75(2): p. 414-26. 
94 
 
133. Maines, M.D., et al., THE OXIDOREDUCTASE, BILIVERDIN REDUCTASE, IS 
INDUCED IN HUMAN RENAL CARCINOMA - pH AND COFACTOR-SPECIFIC 
INCREASE IN ACTIVITY. The Journal of Urology, 1999. 162(4): p. 1467-1472. 
134. Cho, J.A., et al., Hyperthermia-treated mesenchymal stem cells exert antitumor effects on 
human carcinoma cell line. Cancer, 2009. 115(2): p. 311-23. 
135. Hyperthermia on mesenchymal stem cells (MSCs) can sensitize tumor cells to undergo 
cell deathâ€ International Journal of Hyperthermia, 2008. 24(8): p. 638-648. 
136. Multhoff, G., Activation of natural killer cells by heat shock protein 70. 2002. Int J 
Hyperthermia, 2009. 25(3): p. 169-75. 
137. Fierro, M.T., et al., In vitro and in vivo susceptibility of human leukemic cells to 
lymphokine activated killer activity. Leukemia, 1988. 2(1): p. 50-4. 
138. Kubes, J., et al., Immunological response in the mouse melanoma model after local 
hyperthermia. Physiol Res, 2008. 57(3): p. 459-65. 
139. Philip, P.A., et al., Consensus report of the national cancer institute clinical trials 
planning meeting on pancreas cancer treatment. J Clin Oncol, 2009. 27(33): p. 5660-9. 
140. Solinas, G., et al., Tumor-associated macrophages (TAM) as major players of the cancer-
related inflammation. J Leukoc Biol, 2009. 86(5): p. 1065-73. 
141. Strik, H.M., et al., Models of monocytic invasion into glioma cell aggregates. Anticancer 
Res, 2006. 26(2A): p. 865-71. 
142. Baek, S.K., et al., Photothermal treatment of glioma; an in vitro study of macrophage-
mediated delivery of gold nanoshells. J Neurooncol. 104(2): p. 439-48. 
143. Aderem, A. and D.M. Underhill, Mechanisms of phagocytosis in macrophages. Annu 
Rev Immunol, 1999. 17: p. 593-623. 
144. Raynal, I., et al., Macrophage endocytosis of superparamagnetic iron oxide 
nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest 
Radiol, 2004. 39(1): p. 56-63. 
145. Zhang, Y., N. Kohler, and M. Zhang, Surface modification of superparamagnetic 
magnetite nanoparticles and their intracellular uptake. Biomaterials, 2002. 23(7): p. 
1553-1561. 
146. Doi, C., et al., Cytotherapy with naive rat umbilical cord matrix stem cells significantly 
attenuates growth of murine pancreatic cancer cells and increases survival in syngeneic 
mice. Cytotherapy. 12(3): p. 408-17. 
147. Basel, M.T., et al., Cell-delivered magnetic nanoparticles caused hyperthermia-mediated 
increased survival in a murine pancreatic cancer model. Int J Nanomedicine. 7: p. 297-
306. 
148. Appenheimer, M.M., et al., Impact of fever-range thermal stress on lymphocyte-
endothelial adhesion and lymphocyte trafficking. Immunol Invest, 2005. 34(3): p. 295-
323. 
149. How is the immune response affected by hyperthermia and heat shock proteins? 
International Journal of Hyperthermia, 2005. 21(8): p. 713-716. 
150. Chen, T., et al., Chemokine-containing exosomes are released from heat-stressed tumor 
cells via lipid raft-dependent pathway and act as efficient tumor vaccine. J Immunol. 
186(4): p. 2219-28. 
151. Fuggetta, M.P., et al., In vitro effect of hyperthermia on natural cell-mediated 
cytotoxicity. Anticancer Res, 2000. 20(3A): p. 1667-72. 
95 
 
152. Ito, A., H. Honda, and T. Kobayashi, Cancer immunotherapy based on intracellular 
hyperthermia using magnetite nanoparticles: a novel concept of â€œheat-controlled 
necrosisâ€• with heat shock protein expression. Cancer Immunology, Immunotherapy, 
2006. 55(3): p. 320-328. 
153. Manjili, M.H., et al., Cancer immunotherapy: stress proteins and hyperthermia. Int J 
Hyperthermia, 2002. 18(6): p. 506-20. 
154. Milani, V. and E. Noessner, Effects of thermal stress on tumor antigenicity and 
recognition by immune effector cells. Cancer Immunol Immunother, 2006. 55(3): p. 312-
9. 
155. Segal, B.H., et al., Heat shock proteins as vaccine adjuvants in infections and cancer. 
Drug Discovery Today, 2006. 11(11â€“12): p. 534-540. 
156. Tumour infiltrating host cells and their significance for hyperthermia. International 
Journal of Hyperthermia. 26(3): p. 247-255. 
157. American cancer society prostate cancer key statistics.  2013  [cited; Available from: 
http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. 
158. Quinn, D.I., et al., Docetaxel and atrasentan versus docetaxel and placebo for men with 
advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 
trial. Lancet Oncol. 14(9): p. 893-900. 
159. Scher, H.I., et al., Increased survival with enzalutamide in prostate cancer after 
chemotherapy. N Engl J Med. 367(13): p. 1187-97. 
160. Lim, W.A., Designing customized cell signalling circuits. Nat Rev Mol Cell Biol. 11(6): 
p. 393-403. 
161. Walters, J., et al., A constitutively active and uninhibitable caspase-3 zymogen efficiently 
induces apoptosis. Biochem J, 2009. 424(3): p. 335-45. 
162. Pop, C., et al., Mutations in the procaspase-3 dimer interface affect the activity of the 
zymogen. Biochemistry, 2003. 42(42): p. 12311-20. 
163. Bok, R.A., et al., Patterns of protease production during prostate cancer progression: 
proteomic evidence for cascades in a transgenic model. Prostate Cancer Prostatic Dis, 
2003. 6(4): p. 272-80. 
164. Storr, S.J., et al., The calpain system and cancer. Nat Rev Cancer. 11(5): p. 364-74. 
165. Ke, S.H., et al., Optimal subsite occupancy and design of a selective inhibitor of 
urokinase. J Biol Chem, 1997. 272(33): p. 20456-62. 
166. Kelly, J.C., et al., Profiling of calpain activity with a series of FRET-based substrates. 
Biochim Biophys Acta, 2009. 1794(10): p. 1505-9. 
167. Yoshida, E., et al., Enhancement of the expression of urokinase-type plasminogen 
activator from PC-3 human prostate cancer cells by thrombin. Cancer Res, 1994. 54(12): 
p. 3300-4. 
168. Thomas, P. and T.G. Smart, HEK293 cell line: a vehicle for the expression of 
recombinant proteins. J Pharmacol Toxicol Methods, 2005. 51(3): p. 187-200. 
169. Chen, R., et al., Mammalian glycophosphatidylinositol anchor transfer to proteins and 
posttransfer deacylation. Proc Natl Acad Sci U S A, 1998. 95(16): p. 9512-7. 
170. Rothenberg, M.L., D.P. Carbone, and D.H. Johnson, Improving the evaluation of new 
cancer treatments: challenges and opportunities. Nat Rev Cancer, 2003. 3(4): p. 303-9. 
171. Richmond, A. and Y. Su, Mouse xenograft models vs GEM models for human cancer 
therapeutics. Dis Model Mech, 2008. 1(2-3): p. 78-82. 
96 
 
172. Kelland, L.R., Of mice and men: values and liabilities of the athymic nude mouse model 
in anticancer drug development. Eur J Cancer, 2004. 40(6): p. 827-36. 
173. Sausville, E.A. and A.M. Burger, Contributions of human tumor xenografts to anticancer 
drug development. Cancer Res, 2006. 66(7): p. 3351-4, discussion 3354. 
174. Teicher, B.A., M. Liu, and D. Hicklin, Human Tumor Xenograft Efficacy Models, in 
Tumor Models in Cancer Research. 2011, Humana Press. p. 99-124. 
175. Garber, K., Realistic rodents? Debate grows over new mouse models of cancer. J Natl 
Cancer Inst, 2006. 98(17): p. 1176-8. 
176. Sharpless, N.E. and R.A. Depinho, The mighty mouse: genetically engineered mouse 
models in cancer drug development. Nat Rev Drug Discov, 2006. 5(9): p. 741-54. 
177. Schook, L., et al., Swine in biomedical research: creating the building blocks of animal 
models. Anim Biotechnol, 2005. 16(2): p. 183-90. 
178. Swanson, K.S., et al., Genomics and clinical medicine: rationale for creating and 
effectively evaluating animal models. Exp Biol Med (Maywood), 2004. 229(9): p. 866-
75. 
179. Duran-Struuck, R., et al., Myelogenous leukemia in adult inbred MHC-defined miniature 
swine: a model for human myeloid leukemias. Vet Immunol Immunopathol. 135(3-4): p. 
243-56. 
180. Cho, P.S., et al., Establishment of transplantable porcine tumor cell lines derived from 
MHC-inbred miniature swine. Blood, 2007. 110(12): p. 3996-4004. 
181. Adam, S.J., et al., Genetic induction of tumorigenesis in swine. Oncogene, 2007. 26(7): p. 
1038-45. 
182. Finnie, N.J., et al., DNA-dependent protein kinase defects are linked to deficiencies in 
DNA repair and V(D)J recombination. Philos Trans R Soc Lond B Biol Sci, 1996. 
351(1336): p. 173-9. 
183. Notarangelo, L.D., Primary immunodeficiencies. J Allergy Clin Immunol. 125(2 Suppl 
2): p. S182-94. 
 
  
